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ABSTRACT 
The first standardized methods for in vitro drug release testing of solid 
dosage forms were first introduced in the 1960s. Drug release testing has since 
become an important analytical measure along all stages of the drug development 
process. Despite the expanded role of dissolution testing and innovations in the 
types of dosage forms reaching the market, the fundamental methods and 
approaches to dissolution testing have not changed from their original introduction. 
This lack of innovation and one-size-fits-all approach to drug release testing has 
led to inefficiencies in testing and limited the scope of applications where this type 
of information could have an impact. In order to meet this need, we have designed, 
characterized, and implemented a small volume drug release test using ultrasonic 
agitation to screen for differences in dosage form composition. Our approach aims 
to supplement official methods for use during multiple stages of the drug 
development process. The hydro-acoustic environment in the system was 
characterized as a function of input power and position of the acoustic source. 
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Drug release behavior from tablets was also studied over these system 
parameters, and a preliminary mechanistic explanation is made linking the two. 
The interplay between fragmentation and diffusion on solid dissolution processes 
was then explored through a deterministic partial differential equation model. This 
model provides the first instance of time-evolving particle size distributions in a 
dissolution model. In the final sections of this dissertation, uses of the ultrasonic 
agitation mediated drug screening method are demonstrated at two different parts 
of the drug development process – during early formulation development for the 
study of composite microparticle matrix structure on drug release behavior and 
post market surveillance for the screening of substandard tablets. 
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CHAPTER 1: INTRODUCTION 
 
Dissolution testing, or in vitro drug release testing, refers to the study of how 
active pharmaceutical ingredient is released over time from solid dosage forms. 
Since the first standardized methods were introduced in the 1960s, dissolution 
testing has been expanded for use throughout the entire dosage form development 
process –the characterization of active pharmaceutical ingredient (API) and 
dosage form during the drug discovery and formulation development phase1–3, the 
prediction of in vivo performance and the development of in vitro-in vivo 
correlations4–6, and quality control during and after dosage form manufacturing7–
10. This testing is crucial in protecting the $1 trillion global pharmaceutical market, 
supporting innovation in new medicines, and ensuring the efficacy of products 
treating illness. Despite the expanded role of dissolution testing and innovations in 
the types of dosage forms reaching the market, the fundamental methods and 
approaches to dissolution testing have not changed from their original introduction. 
There exists a deeply-rooted, implicit belief that all dissolution methods need to 
relate to and mimic physiological hydrodynamic conditions, despite the fact that 
USP explicitly states that their methods are not meant to mimic in vivo 
environments. The inflexibility of drug release approaches and the assumption that 
these methods be somehow linked to physiological conditions severely limits the 
design space of new methods and reduces the overall efficiency of drug release 
testing at several points along the drug development process. 
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Drug release data collected from any well characterized and discriminatory 
methods can provide fundamental information on dosage form composition. This 
underlying assumption that in vitro conditions must be linked to in vivo conditions 
imposes a strict and unnecessary constraint on the design space of new drug 
release testing methods. While the tests that do allow for the prediction of in vivo 
dissolution behavior will always be necessary, the current methods to achieve this 
come with a high resource cost, both in terms of amount of media and dosage form 
sample needed, which places a large burden on tests that don’t need to meet this 
standard. Rapid and accessible methods of obtaining information about dosage 
form composition would add value at multiple stages of the dosage form 
development and quality control pathways; however, few, if any, new methods 
focus on these properties. Screening methods to assess relative differences in 
dosage form composition could provide this information at increased throughput 
and reduced costs relative to current and traditional methods, and this information 
can be used to better allocate resources for traditional methods if and when further 
testing is required. 
In order to meet these needs, this dissertation presents the development, 
characterization, and application of a small volume drug release test using 
ultrasonic agitation to screen for differences in dosage form composition. Our 
approach aims to supplement official methods to expand uses to multiple stages 
of the drug development process. 
Chapter 2 introduces drug release testing from a historical perspective 
3 
 
 
starting with early studies in solid dissolution, the first connections of these studies 
to pharmaceutical products, and the introduction and evolution of dissolution 
testing. The uses of dissolution testing through the drug development process are 
discussed. In addition, the composition and manufacture of solid dosages forms is 
discussed, and current challenges and new directions are introduced. This chapter 
ends with an overview of the current state of the literature on drug release testing 
methods. 
Chapter 3 introduces ultrasonic agitation as an alternative means to drive 
drug release from solid dosage forms and details the development of the ultrasonic 
agitation mediated release method. This test facilitates the release of drug from 
solid dosage forms through the application of acoustic energy to a liquid medium 
via an ultrasonic horn. This chapter begins with a discussion on ultrasound and 
ultrasonic reactors as well as approaches to drug release profile analysis. Various 
experimental approaches are described to study both drug release behavior and 
the hydro-acoustic environment as a function of the applied acoustic energy. 
Findings from these studies are discussed and used to propose a possible 
mechanism controlling drug release behavior in this system. 
Chapter 4 introduces a new drug dissolution model to the literature that 
incorporates the active tracking of time-evolving particle size distributions. The 
chapter begins by introducing previous approaches to drug release modeling. In 
the model presented here, solid dissolution is treated as a process controlled by 
the 2 interdependent phenomena of diffusive mass removal and physical fracture. 
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The model presented here is used to explore the individual effects and the interplay 
of these 2 phenomena on the overall dissolution process. The chapter concludes 
with a discussion on the implications of the fracturing process and evolution of 
particle size distributions on drug release from solid dosage forms. 
Chapters 5 and 6 demonstrate uses of the small volume, ultrasonic agitation 
mediated test at two different stages of the drug development process – 
experimental dosage form development and post market surveillance. In chapter 
5, composite microparticles are introduced as novel dosage forms that address 
limitations and challenges in current formulation development and manufacturing 
approaches. The small volume drug release test is applied during early formulation 
development for the study of composite polymeric microparticle matrix structure 
on drug release behavior. Composite hydrogel particles are used to compare the 
discriminatory power of the ultrasonic agitation mediated test to official test 
methods. The small volume test facilitates release behavior screening from these 
types of samples that are produced at small scales by greatly reducing the amount 
of sample needed to be produced per test. 
Chapter 6 describes applications of the small volume drug release method 
in post-market surveillance of pharmaceutical products. The chapter begins with a 
discussion on the issue of poor-quality medicines. Different strategies for the 
detection of these products are analyzed, and small volume drug release testing 
is introduced as a method for portable screening of dosage form composition. This 
chapters details the efforts to incorporate the ultrasonic agitation mediated method 
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into a portable and automated testing platform developed in the Zaman lab. The 
chapter concludes with a discussion on the challenges of performing drug release 
testing at the point-of-care and how the method described in this dissertation can 
overcome these challenges. 
Chapter 7 provides concluding remarks discussing the impact and 
innovation of the work described, limitations of the method and results, and future 
directions towards further fundamental characterization, optimization, and 
applications of the small volume, ultrasonic agitation mediated drug release 
screening test. 
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CHAPTER 2: BACKGROUND 
 
Tablets, pills, and capsules are ubiquitous in the delivery of pharmaceutical 
and therapeutic payloads. The first written documentation of therapeutic 
substances incorporated into a solid dosage comes from Ancient Egypt – a 
medical papyrus dated to 1500 BC detailed the recipes for combining medicinal 
plant materials with bread dough, honey, and grease to form small, hard balls. 
Pliny, a Roman scholar, was the first to start describing medicines in this form as 
pilula, or pills, in the 1st century AD. The modern era of tablet production was 
ushered in by a patent filed in 1853 by William Brockendon describing the shaping 
of pills, lozenges, and black lead by pressure in dies11. Today, tablets make up 
80% of medicine sales by volume; 4.5 billon prescriptions were issued in 2016 
during 2016 in the United States alone, and this number does not take into account 
over-the-counter sales of medicines, supplements, and other therapeutic agents. 
Despite, their long history of use, our current understanding of how solid dosage 
forms deliver drug in the body is only about 70 years old. The composition and 
physical features of tablets and other solid dosage forms are now widely 
appreciated in their impact on the rate at which drug is released from the dosage 
form and taken up by the body. This realization highlighted the importance of 
reproducibility and quality control measures in the production of tablets as small 
changes in formulation can have widely varying effects on tablet performance. 
Pharmaceutical scientists have also taken advantage of these properties to 
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develop controlled and sustained release dosage forms. Methods and 
technologies for assessing drug release behavior from pharmaceutical products 
were first introduced in the scientific literature in the 1960s and 1970s. These tests 
were initially used to investigate differences in clinical outcomes of medicines on 
the market. Since then, drug release testing, or dissolution testing, has been 
incorporated into many parts of the drug development process and manufacturing 
process.  
 
Solid dissolution and first connections to the pharmaceutical sciences 
Initial experiments and observations on the process of solid dissolution can 
be dated back to 1790; James Keir reported on the dissolution and precipitation of 
metal ions in nitrous acid and vitriol for use in separating silver from various other 
metals12. One hundred years later, Arthur A Noyes and Willis R Whitney provided 
the first mathematical description of the rate of solution of a solid in the literature, 
recognizing solid dissolution as a scientifically important phenomenon13. 
Subsequent studies over the first half of the 20th century expanded on the 
relationship proposed by Noyes and Whitney as well as explored different 
mechanisms. These studies were conducted in the fields of chemistry and 
chemical engineering and focused on the applications of dissolution in industrial 
relevant processes, such as the solubilization and parting of metals, manufacturing 
of textiles, and improving reaction rates of poorly soluble species14–17.  
8 
 
 
Dissolution of drug products in solid form did not gain critical appreciation 
in the pharmaceutical sciences until the 1950s. Tablets were designed to swell and 
break into smaller pieces upon addition to aqueous media, a process known as 
disintegration. Up until this point, while the availability of drug in the body was 
known to be a vital parameter for clinical effectiveness, disintegration of tablets 
was thought to be the main driver of in vivo availability18,19.  Edwards provided 
perhaps the first link of the rate of dissolution to the underlying physiology 
experienced by an ingested tablet; he described the importance of the pH levels 
and amount of fluid in the stomach and GI tract pre- and post- meals and 
speculated that dissolution was the rate limiting step in bioavailability for a drug 
that is freely absorbed and noted the importance of pH levels, fluid levels in the GI 
tract, and fasted vs fed conditions on this rate20. Nelson took this a step further and 
correlated in vitro dissolution rates to in vivo levels of drug, comparing calculated 
and measured in vitro solution rates of various salt forms of theophylline across 
pH to blood levels of due to different salt forms, while discussing the importance 
of tablet physical properties to blood levels21. 
Through the 60s and 70s, numerous studies demonstrated the effects of 
dissolution rate on drug efficacy and bioavailability, or the amount of drug reaching 
the general circulation22–26. Importantly, the role of dosage form formulations in 
controlling dissolution behavior became widely appreciated. To highlight a few 
cases, in 1960, Levy and Hayes attributed varying effectiveness and onset of 
gastrointestinal side-effects to differences in rate of solution of acetylsalicylic acid 
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tablets from different manufactures22. In 1963, poor dissolution behavior was 
determined to be the root cause of physiological inactivity of prednisone tablets27. 
In both cases, tablets passed disintegration tests despite their poor dissolution 
behavior. Perhaps the clearest demonstration of this connection came from 
improper dosing cases of digitoxin in 1971 and phenytoin in 1968. Exploratory 
studies into the formulation of digitoxin tablets showed that serum levels of 
digitoxin could vary up to sevenfold with changes in product formulation28,29. This 
sparked a wide and in-depth study of the dissolution characteristics of 44 lots of 
32 manufacturers of digitoxin tablets revealing differences in dissolution behavior 
between manufacturers as well as lots from the same manufactures30. This study 
provided early evidence for dissolution testing as a quality control measure. A 
change of one non-drug ingredient of phenytoin tablets was determined to be the 
cause of a large number of phenytoin toxicity cases in Australia and New Zealand 
in 196831. Replacing calcium sulfate with lactose was determined to increase the 
dissolution rate of phenytoin through the increased hydrophilicity of the lactose 
resulting in an increase in serum levels into toxic levels32. In all of these cases, 
dissolution tests were used forensically to assess root causes of abnormal in vivo 
behavior.  
 
Initiation and Evolution of Official Dissolution Testing 
 The research conducted between 1950-1970 solidified the importance of 
dosage form formulation and manufacture processes in affecting drug release 
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behavior as well as the overall connection to bioavailability. During this same time 
period, studies exploring the underlying principles of dissolution test methods 
started to appear in the literature. Stirring speed and overall rate of agitation were 
found to cause deviations of release kinetics away from those described by Hixon 
and Crowel33. A dissolution test’s ability to detect expected differences in release 
behavior diminishes if rates are increased past a certain threshold. Hamlin et al. 
attributed this observation to minimization of the diffusion layer surrounding the 
dissolving species; the lower bound of this diffusion layer is dependent on the 
dissolving species and also the dissolution method34. Studies also focused on the 
role and effect of the dissolution media on the drug release process. The addition 
of surface active agents, or surfactants, to aqueous media increases the solubility 
of poorly soluble drugs, mainly through the formation of micelles, resulting in an 
increase in the rate of solution of these poorly soluble compounds. The addition of 
higher levels of surfactant eventually led to a decrease in dissolution rate due to 
increases in media viscosity. An optimal surfactant concentration was found to 
exist that maximizes dissolution rate35,36.  
These early tests used a variety of different apparati and approaches to 
perform drug release testing; Figure 2.1 displays an image of a mechanism made 
by Maney in 1941 to perform disintegration tests24. Variations on the paddle-stirred 
tank were most common. Most apparati used paddle stirrers. Tests were 
performed at volumes ranging from 250 mL up to 2 L in vessels of various 
geometries. Tests were performed at either 25 °C or 37 °C. Stirring speeds ranged 
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from as low as 59 rpm up to 500 rpm. Most tests required manual sampling and 
sample preparation although 2 studies employed custom automated sampling and 
measurement systems37,38. The apparatus for USP disintegration tests was also 
repurposed for dissolution tests in some studies. The growing understanding of the 
effects of the dissolution method on drug release results highlighted the necessity 
for standardized methods to perform this testing. 
 Recognizing the need for standardized testing conditions, the United States 
Pharmacopeia (USP) and the National Formulary (NF) introduced the basket-
stirred flask in 6 monographs published in 1971. The paddle-stirred flask was 
introduced in 1980. Today, dissolution testing is defined in over 700 monographs, 
almost all which use apparatus I and II, or the basket-stirred flask or paddle-stirred 
flask, respectively39. USP currently supports 7 official apparati to perform 
dissolution testing, and apparati 1-4 have been harmonized across pharmacopeias 
globally and included in the International Pharmacopeia published by the World 
Health Organization (WHO). The harmonized USP general chapter <711> 
Dissolution provides a description of apparatuses I-IV, including standardized 
dimensions and operating parameters; for apparatus II, these parameters include 
the defining dimensions of the paddle, the tolerances on paddle and shaft 
dimensions, the positioning of the paddle in the vessel, and the volume of the test 
vessel40. Figure 2.2 displays a commercial USP II apparatus along with a 
schematic of the paddle found in the USP general chapter. These apparati are now 
widely recognized as the official approaches to dissolution testing, and they have 
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been employed across a variety of purposes for dissolution testing across the drug 
development process. 
  
Dissolution Testing Throughout the Drug Development Process 
 The Food and Drug Administration (FDA) breaks the drug development 
process into 5 broad stages. In the discovery and development stage, basic 
physiochemical properties of potential chemical moieties are explored. Initial 
formulation development steps are performed to convert raw crystals of active 
pharmaceutical ingredient (API) into a form that is deliverable to the human body. 
The formulation plays multiple roles to this end, including stabilizing the API, 
influencing solubility and absorption properties, and protecting the API from harsh 
environments, and controlling the rate of drug release. Formulation development 
is an iterative process that occurs over the first 4 stages. In the preclinical stage, 
data from in vitro and in vivo experiments are used to support Investigational New 
Drug applications (IND). Once an IND is approved, the drug candidate moves into 
the clinical trial stage where the drug product is tested in humans in increasingly 
complex trials to determine the efficacy, the proper dosages, safety, and side 
effects. A New Drug Application is submitted for drugs that perform well in all 
clinical trials. The FDA review stage can take up to 10 months. After approval, drug 
performance and safety are monitored as part of the FDA post market drug safety 
monitoring stage. The entire process to bring a new drug product to market can 
take 10-15 years41. Only about 5 out every 5000-10000 drug candidates make it 
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out of pre-clinical studies, and only 1 of these 5 drugs gets FDA approval, on 
average. Innovation in approaches to reduce the time to FDA approval or increase 
the success rate could reduce the cost to bring a new drug product to market.  
 Dissolution testing plays different roles across all stages of the drug 
development process and manufacturing42. Figure 2.3 provides an overview the 
various functions. The following sections describe the uses of dissolution and in 
vitro release testing along the drug development process. 
 
Drug Discovery and Early Development 
 The characterization of identified candidate molecules involves the 
determination of the solubility limit and rate of solution of the species in aqueous 
media of varying pH. Drug release testing is used to explore drug-substance 
characteristics, such as particle size, intrinsic solubility, and crystal form. Initial 
formulation development proceeds with this information, and various formulations 
are tested to determine their overall effect on stability, solubility, and dissolution 
behavior. The main purpose of dissolution testing at this step is to determine if 
changes in formulation result in differences in drug release behavior43. 
Pharmaceutical engineers and formulation scientists are also interested in 
developing new processes for solid dosage form development44. In both cases, 
manufacturing at this stage is performed in small-batch and as needed. This 
process is typically time-consuming and labor intensive. Drug release testing at 
this step is costly due to the low amount of sample available, especially if the 
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number of formulations to screen is high. Small volume methods would help 
alleviate some of this burden. 
 
Pre-Clinical Testing 
 Pre-clinical testing assesses the efficacy, toxicity, and safety of both the API 
and the formulation in which it is delivered in both cell assays and animal models. 
The main uses of in vitro drug release testing during this step are to facilitate the 
development of the prototype formulation to be used in the first round of clinical 
trials, inform formulation development for toxicology studies, and supplement 
pharmacokinetic data from animal studies.  
 
Clinical Trials 
 Dissolution testing in the clinical trial phase is mostly focused on 
establishing an in vitro in vivo correlation (IVIVC) or relationship (IVIVR). The 
Biopharmaceutical Classification System (BCS) was proposed in 1985 to provide 
a framework for defining in vivo behavior based on the aqueous solubility and the 
intestinal permeability of the dosage form: high solubility/high permeability (class 
I), low solubility/high permeability (class II), high solubility/low permeability (class 
III), low solubility/low permeability (class IV)5. The classification of a drug product 
determines the protocol for dissolution testing and sets the burden of testing 
necessary to form and IVIVC and the overall applicability of in vitro release data 
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as a prognostic tool for regulatory purposes4,45. IVIVCs allow the groups to file for 
biowaivers which can significantly reduce the testing burden46. Dissolution testing 
during this time is also used to guide process development throughout this stage47. 
 
Manufacturing and Scale-Up 
 Dissolution testing during manufacturing is used to assess the effects of 
process changes and scale-up on product quality. Drug release rate is defined as 
a Critical Quality Attribute (CQA) and studied as a function of critical material 
attributes (CMA) and critical process parameters (CPP) to define a design space 
for the formulation48,49. The FDA defines dissolution approaches in the scale-up 
and post approval changes for both immediate, extended, and modified release 
dosage forms. Dissolution testing is also used to ensure batch-to-batch 
consistency6,50,51.  
 
Post Market Quality Assessment 
 Dissolution testing is used investigate the quality of medicines that result in 
abnormal clinical outcomes10. Dissolution testing is also part of a suite of tests to 
monitor the quality of pharmaceutical products on the market and screen for 
substandard and counterfeit medicine, a problem that disproportionately affects 
low and middle income countries8. 
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Solid Dosage Forms 
Manufacturing of Tablets 
 Solid dosage forms are composed of 2 types of ingredients – the API and a 
range of non-drug ingredients, referred to as excipients. Manufacturing of tablets 
from these 2 starting materials requires a multi-step and energy intensive process 
performed at the batch scale. Figure 2.4 displays the general steps required to go 
from raw ingredients to tablet products52. APIs are converted to solid starting 
materials through a process called crystallization. Batch crystallization techniques 
result in heterogeneous crystal size populations, and the outputs of this process 
need to be milled. The crystallized API is then blended with excipients to create a 
well-mixed powder. This powder mixture undergoes a process known as 
granulation to produce a population of API-excipient agglomerates. The 
agglomerate mixture is sieved and compacted into the final tablet product. 
Ingredients are often sourced from different locations around the world with 
multiple facilities handling various production processes.  
 Flowability, compressibility, and compactability are all important factors of 
the overall powder blend53,54. The handling and transport of powder intermediates 
between the individual steps needs to be predictable and repeatable. Additional 
excipients are often required to coat the inside of the powder feeders and die casts 
to prevent the material being tableted from adhering to the walls and causing 
irregularities in the amount of powder in each tablet. Compressibility, the amount 
the powder mixture can be pressed on itself, and compactability, the propensity for 
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the powder to form a compact, are also heavily dependent on the material 
properties and composition of the powder mixture. 
The process is heavily dependent on the API and excipients being 
considered. Small differences in the initial properties of the starting materials, from 
the relative amounts of all material used down to the molecular form of the API can 
greatly impact final tablet properties55. A highly regulated and controlled tablet 
manufacturing process is essential to ensure batch-to-batch quality. Any changes 
made to the protocol, either minor recipe changes or full manufacturing changes 
involved in production scale up, must be verified to ensure tablet properties are not 
affected51,56. 
 
Formulation Development 
Excipients play many roles in solid dosage forms. API crystals are often not 
suitable for direct compaction into tablets – the crystals display low flowability, 
compactability, and compressibility, the solubility and release properties of the API 
are not favorable, etc. Excipients can be added to improve the physical properties 
of the tablet mixture, the stability of the API in the final tablet product, and the 
solubility and absorption properties of the API.  
The material properties and the composition of these ingredients determine 
the material properties and, in turn, the performance of the final product. The 
material properties over every length scale – molecular structure, crystal structure, 
granule structure, and tablet structure – need to be considered55. Drug molecules 
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can differ in solid form such as polymorph, hydrates, and salts, and these 
differences result in widely different physiological properties. Tablet microstructure 
bridges the gap between the molecular and crystal properties and the overall tablet 
performance. Porosity of the tablet plays an important role in the tablet hardness 
and friability as well as performance parameters. The shape and roughness of 
particle components also determine the overall physical properties of the final 
tablet, as well as the drug release rate.  
Immediate release dosage forms typically swell and disintegrate into 
smaller particles upon exposure to aqueous media57. This process of disintegration 
greatly increases the surface area available for dissolution. Tablet microstructure 
and the excipient blend used need to allow for the rapid uptake of aqueous media 
into the tablet. These tablets can also contain excipients that aid in the solubility of 
hydrophobic species, through complexation or by inducing local supersaturation58. 
Formulations can also be prepared to allow for controlled or sustained 
release products59–62. Enteric coatings are a simple example of a controlled 
release product; the coating only disintegrates in the pH range of the small 
intestine protecting the drug from the more acidic environment in the stomach24. 
Controlled and sustained release dosage forms act through many different 
mechanisms. Tablets can be formed in layers, with each layer tuned to release 
drug at a different rate. Monolithic dosage forms do not disintegrate, forcing drug 
release to occur from the surface of the single object. Drug payloads can be loaded 
into various types of microstructures in a process known as microencapsulation. 
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Drug release is typically controlled by diffusion, polymer erosion, or a combination 
of both63,64. 
More complex formulations have been developed that allow for the inclusion 
of multiple APIs of different properties in one tablet. These products are referred 
to as fixed dose combination (FDC) tablets, and they help reduce the patient 
burden of taking multiple medications. The product Winthrop, made by Sanofi, is 
an FDC tablet containing the antimalarial drugs artesunate and amodiaquine; each 
drug is loaded into 2 distinct hemispheres1.  
 
Complications 
 Hydrophobic drugs moieties account for 40% of all pharmaceutical 
compounds approved by the FDA since 1980 and 70% of potential candidates 
today65. The limited solubility of these drugs poses a challenge to develop 
formulations for oral delivery due to poor bioavailability58. To increase the 
bioavailability and physiochemical properties of hydrophobic materials, there has 
been a push towards nanoscale systems66. API crystals in the nanoscale regime 
have been shown to have greatly increased solubility and dissolution rates 
compared to the micron-plus sized crystals that result from current processes. 
Batch approaches to crystallization pose challenges in the control of crystal 
product characteristics and scale-up. Controlling of the crystallization process 
starts with a well-defined and consistent process for nucleation. This is impossible 
to achieve in a stirred-tank, as nucleation is often induced by interaction with a 
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seed, such as a dust particle, or the sidewalls of the tank; supersaturation also 
displays spatial heterogeneity54. These processes are incapable of generating 
nano-sized crystals and require the use of secondary formulation steps that can 
result in degradation and polymorphic transformation of the API65. Conventional 
methods for nanocrystal formation include jet milling, high-pressure 
homogenization, and anti-solvent precipitation. More recent approaches involve 
the use of microfluidics in co-formulation of drug and excipient and loading of 
hydrogel matrices with nanoparticles or emulsions; these approaches will be 
discussed further in Chapter 5. 
 
New Approaches to Dissolution and Drug Release Testing 
Recent literature has focused on developing new types of dissolution tests 
to create more physiologically relevant tests as well as accommodate novel 
dosage forms, low dose medications, and early development stage drugs. The bulk 
of these systems aim to produce more biologically representative hydrodynamic 
conditions. A dissolution test that more accurately mimics the physiological 
environment in the body is needed to make accurate predictions about in vivo 
performance of a tablet which has huge implications in the drug development 
phase47. Flow-through apparati have been developed to better mimic the 
hydrodynamic and mechanical environment experienced by a tablet as it travels 
through the gastrointestinal tract; some efforts have incorporated peristaltic 
contractions to replicate movement through the intestines while others have 
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developed artificial stomach and intestinal models67–69. These types of systems 
are gaining interest in part because traditional tests fail to correlate in vitro release 
profiles to in vivo results for extended release formulations67. Compendia tests 
have also been modified to induce mechanical forces experienced along the 
gastrointestinal tract. For example, beads have been added to Apparatus 3 
reciprocating cylinder devices, and novel ways to explore shear-induced 
dissolution in stirring based methods have been reported70,71. 
 
Small Volume Drug Release Testing 
Small volume dissolution testing has been reported in the literature using 
volumes as low as 25 mL. Reducing media volume increases the analytical power 
of the test allowing for the analysis of low-dose medicines and the use of smaller 
amounts of API in general72,73. The latter case is of particular interest to drug 
development companies in the early stages of drug discovery where the drug of 
interest is produced in low quantities. Typical approaches involve miniaturizing the 
paddle stirrer approach, and commercial vendors of compendia apparatuses offer 
conversion kits to accommodate the miniaturized system73,74. Small volume 
dissolution testing has been shown to increase discriminatory power when testing 
immediate release dosage forms74. Particular attention has been given to 
differences in the hydrodynamic environment in compendium vs small volume 
systems. These systems display different flow behavior with similar paddle rotation 
speeds resulting in different rates of drug release in each system75,76. This 
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difference is a major reason that small volume dissolution testing is not considered 
an official test. Despite the unique benefits and promise of alternative dissolution 
methods demonstrated in the literature, there is a very high barrier to becoming an 
officially recognized test. 
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Figure 2.1. Early Apparatus for Disintegration and Dissolution Testing.  
Mechanism developed by Maney and Kuever to best simulate the condition found 
in the gastro-intestinal tract. Image taken from Maney and Kuever 194124. 
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Figure 2.2. USP Apparatus II.  
(A) Commercially available instrument with 8 test vessels. Test vessels each hold 
1L. Image taken from pharmapproach.com. (B) Schematic of paddle. Taken from 
from USP <711>40. 
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Figure 2.3. Uses of In Vitro Dissolution Studies.  
Overview of various uses of in vitro dissolution studies throughout drug 
development process. Figure taken from Jamzad et al. 200642. 
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Figure 2.4. Tablet Manufacturing Process.  
API crystals are milled to produce more homogeneous crystal size distribution. 
Milled crystals are blended with excipients, and this mixture undergoes granulation 
to form drug-excipient agglomerates. These agglomerates are sieved and 
compacted into tablets. Figure taken from Leon et al. 201452. 
  
27 
 
 
CHAPTER 3: DEVELOPMENT AND CHARACTERIZATION OF AN 
ULTRASONIC AGITATION MEDIATED DRUG RELEASE TEST 
 
Drug release testing is an important analytical tool that has been applied 
throughout the drug development process since its official introduction 50 years 
ago. Despite the expanded role of dissolution testing and innovations in the types 
of dosage forms reaching the market, the fundamental methods and approaches 
to dissolution testing have not changed from their original introduction. This lack of 
innovation and one-size-fits-all approach to drug release testing has led to 
inefficiencies in testing and limited the scope of applications where this type of 
information could have an impact. In particular, small volume methods would 
reduce the amount of sample needed for testing in early formulation development 
and enable applications of portable drug release screening. 
The underlying assumption that in vitro conditions must be linked to in vivo 
conditions imposes a strict and unnecessary constraint on the design space of new 
drug release testing methods. Drug release data collected from any well 
characterized and discriminatory method can provide fundamental information on 
dosage form composition. Previous attempts of small volume dissolution in the lab 
found traditional stirring based methods to be cumbersome and pose cross-test 
contamination risks; the use of stir bars raised issues with partitioning the 
dissolving species and the stirring element. Ultrasonic agitation was explored as a 
possible alternative because it minimizes contact of the agitation source with the 
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test solution, and potentially allows for indirect agitation. Ultrasound has been 
previously shown to increase rates of solid dissolution processes77. 
We seek to address these gaps in dissolution testing by employing 
ultrasonic agitation, with resultant cavitation and acoustic streaming, as a novel 
means to perform drug release testing of tablets in a small volume format. This 
chapter describes the design, development, and characterization of this method. 
An automated, continuous, closed-loop sampling system was designed to 
measure drug release from prednisone tablets. Drug release behavior was studied 
as a function of critical system parameters. The effect of these parameters on the 
acoustic-hydrodynamic environment was studied using streak photography, high 
speed photography methods and local pressure measurements recorded by a 
hydrophone. 
 
Background 
Ultrasound and horn-type ultrasonic reactors 
  Ultrasonic agitation as a mechanism to achieve convection has not been 
explored in the drug release testing literature despite demonstrated benefits in 
solid dissolution processes; ultrasonic agitation increases the surface area of the 
dissolving species and the mass transfer coefficient of the overall process78. The 
application of ultrasound, acoustic waves with frequencies greater than 20 kHz, to 
liquid media produces two unique phenomena: ultrasonic cavitation and acoustic 
streaming. Ultrasonic cavitation refers to the formation, growth, and collapse of 
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gas- or vapor-filled microbubbles in response to pressure fluctuations of the 
acoustic wave. These bubbles are either pre-existing or generated by the tensile 
rarefaction phase of the acoustic wave interacting with micro- or nanoscale 
impurities. The often violent collapse of these microbubbles results in local fluid 
pressures in the GPa regime79, and collapse near solid surfaces results in a 
reentrant jet which can damage and erode soft ceramics80 and even hardened 
steel81. Taken in aggregate, the effects of many tiny cavitation events have been 
shown to increase reaction rates, open unique reaction pathways compared to 
traditional means of mechanical agitation, and fracture and ablate solids; the field 
of Sonochemistry is dedicated to studying these effects82.  
Primary acoustic streaming occurs because a propagating acoustic wave 
generates a body force owing to viscous absorption in the bulk fluid83–85, one 
manifestation of what is generally referred to as the acoustic radiation force86–89. 
The resulting macro-scale fluid flow can further be enhanced by scattering of 
particles and bubbles in the host fluid, a second manifestation of the acoustic 
radiation force. Depending on the intensity of the ultrasonic field and the geometry 
of the test chamber, fluid flow can be laminar, vortical, or turbulent. At the 
microscale, a second boundary-layer streaming flow, often referred to as “micro-
streaming”, will result directly from oscillations of the cavitation bubbles90,91. 
Transport is accelerated by high flow shearing rates occurring at micron-sized 
scales compared to primary acoustic streaming.  
Various experimental techniques and measurement tools have been 
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employed to characterize the fluid flow and acoustic properties of ultrasonic horn 
reactors. Techniques such as streak photography, particle image velocimetry, and 
laser Doppler anemometry have been used to explore fluid flow in these 
systems92–95. Computational techniques have been used to model these 
multiphase flows in the parameter regimes of certain applications96–98. The flow 
generated from the horn is directed downwards from the radiating surface. The 
velocity profile generated resembles a conical jet whose radius increases with 
distance from the tip of the horn. A large cloud of cavitation bubbles forms directly 
underneath the horn, and these bubbles can be scattered into the liquid. The 
macro-scale flow is enhanced by the scattering of these bubbles and of bubbles 
located away from the horn. The conical jet produced by the horn continues 
traveling away from the horn tip until it reaches a boundary. The boundary causes 
recirculation of the flow upwards into the bulk resulting in vortical structures 
throughout the bulk. 
 
 
Analysis of Release Profiles 
 Data from drug release tests are typically reported as percent released 
relative to the expected amount of API in the dosage form40. The number of time 
points required to describe the release behavior from a given dosage form 
depends on the rate of release from the dosage form. For rapidly dissolving 
immediate release tablets, a single time point by which at least 80% of drug release 
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is achieved is sufficient. Dosage forms that display slower release behavior require 
more sampled time points with a sufficient number of data points below 80% 
dissolved. The number of replicates needed to adequately define the release 
behavior of a batch depends on the application. Percent dissolved at each time 
point measurement from all batch replicates can be expressed as the geometric 
mean (GM) and percent coefficient of variation (%CV) of the measurements50. The 
geometric mean and %CV are defined in equations 3.1 and 3.2, 
(Eq. 3.1)     𝐺𝑀 = exp⁡[
1
𝑛
∑ ln(𝑃𝑖)
𝑛
𝑖=1 ] 
(Eq. 3.2)     %𝐶𝑉 = 100% ∗ √exp(𝜎2) − 1 
where P is the percent dissolved and σ2 is the variance of the ln(P) of the samples. 
Other approaches to dissolution profile comparison include statistical, 
model independent, and model dependent methods. Each approach provides 
different results, and the appropriate approach will depend on the goal of the 
analysis. Model independent approaches involve comparisons between mean 
dissolution time, time until a specified percent dissolved (t10%, t50%), and pairwise 
procedures99. The similarity factor (f2), a pairwise procedure, is defined in Equation 
3.3 as the logarithmic transformation of the sum-squared error of differences 
between the GM of the test batch Ti and the GM of the reference batch Ri over all 
time-points100. 
(Eq. 3.3)    𝑓2 = 50 ∗ log⁡([1 +
1
𝑛
∑ |𝑅𝑖 − 𝑇𝑖|
2𝑛
𝑖=1 ]
2
∗ 100) 
Similarity factors are calculated for all time points below 85% released. Two 
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dissolution profiles with an f2 value above 50 are considered similar; a value of 50 
corresponds to a maximum difference between test and reference values at any 
point of 10%100,101. This metric is a popular choice to conduct dissolution profile 
analysis due to the single number output and support from the FDA in the use of 
f2 in batch-to-batch and scale-up testing51. Drawbacks to this metric include failure 
to provide information on the shape of the dissolution profiles or intra-batch 
variability99. Analysis of variation methods can be conducted to compare entire 
dissolution profiles, individual time points to identify where changes in dissolution 
behavior occur, and model independent analyses for a set of tests102,103. ANOVA 
methods are often overly discriminatory, especially when considering 
bioavailability data99. 
 Dissolution efficiency is defined as the area under the dissolution curve over 
a period of time normalized to the area of the rectangle formed by 100% dissolution 
over this time range and is described by the following equation, 
(Eq. 3.4)    DE = ⁡
∫ (𝑓(𝑡)) ∗ 𝑑𝑡
𝑡
0
𝑓𝑚𝑎𝑥 ∗ 𝑡
⁄  
where f(t) is the fraction dissolved at time t, fmax is the maximum achievable fraction 
dissolved, and t is the total length of the drug release test104. Dissolution efficiency 
provides a single quantitative metric to describe a release curve that is based off 
of all data points. This metric allows for comparison between release profiles from 
different batches. Dissolution efficiencies also provide information on intra-batch 
variability and the shape of the dissolution release curve, unlike the fit factor, f2. 
 Model dependent methods will be discussed in detail in Chapters 4 and 5. 
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Ultrasonic Agitation Mediated Kinetic Release Test 
Figure 3.1 displays a schematic of the experimental setup used for drug 
release testing of tablet samples. The ultrasonic cavitation mediated release test 
employed a 40 kHz ultrasonic generator (Vibracell VCX134FSJ; Sonics, Newtown, 
CT). The generator was connected to a transducer fitted with a stepped 
microprobe horn with a tip diameter of 3.18 mm. The microprobe horn was made 
from titanium Ti-6Al-4V and rated to have a peak vibrational amplitude of 180 µm. 
The horn amplitude was set by the ultrasonic generator. This parameter is 
subsequently referred to as amplitude setting and could be adjusted between 20-
100% in 1% increments. A custom stand was designed and built to ensure 
consistent radial placement of the ultrasonic transducer and glass vessel; see 
Appendix A for design schematics of the stand. The stand also allowed for the 
distance between the bottom of the horn and the bottom of the test vessel to be 
adjusted. This distance is subsequently referred to as probe height, and the upper 
and lower limits of the probe height were dictated by the vessel geometry and the 
media volume; for this system the probe height can be adjusted between 35-55 
mm. The media volume for each test was set to 50 mL; this represents a 20x 
decrease from volumes used in USP testing and should provide enough volume 
for complete dissolution of samples with use of co-solvent systems. A 70 mL 
plastic, round-bottom test tube (BRAND ®, Sigma-Aldrich, St. Louis, MO) was 
used as the test vessel. Ultrasound was administered to the test media via the 
microprobe horn at 1 Hz pulse repetition frequency and 50% duty cycle. The test 
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media was sampled continuously via a closed loop system controlled by a 
peristaltic pump (CP 78023-12; Ismatec, Vernon Hills, IL) operated at a flowrate of 
0.85 mL/min. Sampled media was first passed through a 1 µm cannula filter (QLA, 
Telford, PA) submerged in the test vessel. The pre-filtered media was then passed 
through a 0.22 µm pore size inline filter (.25 mm diameter, FLL/MLS CA; GVS Life 
Sciences, Sanford, Maine) before being sent to a flow-through cuvette (0.39 mL, 
10 mm path length; FireFly Sci, Staten Island, NY). The cuvette is placed in a UV-
Vis spectrophotometer (SpectraMax M5; Molecular Devices, San Jose, CA), and 
absorbance of the sampled media was measured at 285 nm. Test media was then 
pumped back to the test vessel. Total system dead-volume was determined to be 
2.80 mL. For a complete description on the setup and use of the ultrasonic 
mediated kinetic release apparatus, see Appendix B. 
 
Characterization of Hydro-Acoustic Environment  
Materials and Methods 
Materials. Glass spheres (10 um average diameter, 10g) were obtained from 
Sigma Aldrich (St. Louis, MO). 
 
Streak Photography to Study Flow Behavior. A cross section of a glass test tube 
(ChemGlass, Vineland, NJ) filled with 50 mL Milli-Q filtered water was illuminated 
by a sheet of light produced by a He-Ne laser (1135P; Uniphase, Manteca, CA) 
fitted with a cylindrical lens (custom). A camera (Grasshopper3; FLiR, Billerica, 
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MA) with a 35 mm lens (Fujifilm, Tokyo, Japan) was set up perpendicularly to the 
illuminated plane at a distance of 250 mm; a schematic of this setup is displayed 
in Figure 3.2A. Images captured were 960 x 600 pixels, and the field of view was 
30.0 mm x 18.8 mm. Neutrally buoyant, glass microspheres of 10 µm average 
diameter were seeded at 0.1% w/V in the test vessel. Ultrasound was administered 
to the test media via the microprobe horn at 1 Hz pulse repetition frequency and 
50% duty cycle for amplitude settings of 45%, 50%, and 60% and probe heights of 
40 mm, 50 mm, and 60 mm. Images were taken every 100 ms for 10 sec during 
horn operation at each parameter configuration tested. The camera shutter speed 
and gain were set at 40 ms and 26.0 dB, respectively. The test media and tracer 
particles were replaced after all amplitude settings were tested at each probe 
height.  
Image processing and analysis were performed using MATLAB 
(MathWorks, Natick, MA); images were sharpened with a Laplacian filter, 
converted to binary, and filtered to remove objects less than 8 pixels long. The 
length of all streak lines in pixels was determined, and each pixel value in an object 
was replaced by the length of the object. The weighted values in a 200 x 200 pixel 
region of interest (ROI) centered above the bottom of the test vessel were 
summed, and this sum was divided by the total number of pixels in the ROI to 
provide a weighted density in the ROI, subsequently referred to as a flow score. 
An average flow score over 10 sec was calculated for each condition. 
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High Speed Photography to Study Cavitation Behavior. A glass tank of dimensions 
40 cm x 20 cm x 25 cm was filled with tap water. The sonication horn with 1/8 in 
diameter tip was inserted to a depth of 1 cm in the center of the tank.  A high-speed 
camera (FASTCAM SA5, Photron, San Diego, CA) with a 200 mm focal length lens 
(AF Micro-Nikkor, Nikon, Melville, NY) was set up in front of the tank along the 20 
cm axis. An LED (PL800, Dolan-Jenner, Boxborough, MA) was placed directly 
behind the tank to provide continuous backlighting of the area directly below the 
horn tip. Image acquisition settings were defined through PFV software (Photron, 
San Diego, CA) and are defined in Table 3.1. The shutter speed of the camera 
was set at 1/253,000 sec, and images were captured for 1 sec at 100,000 fps 
during horn operation. Images were acquired at horn amplitude settings of 20%, 
40%, 60%, 80%, and 100%. 1208 images were saved from each image set. Raw 
images were 8-bit grey scale. 
 To assess bubble cloud density, image processing was performed in 
MATLAB (MathWorks, Natick, MA).  Images were converted to binary with 
threshold value of 0.99, then inverted. An average pixel density was calculated for 
all images in a set in a 247 px x 178 px region located directly below the horn tip. 
 To assess the radii of bubbles at each amplitude setting, image processing 
was performed in ImageJ. Images were converted to binary, and all circular objects 
in an image were identified. Objects with a diameter greater than 300 µm were 
filtered out by setting a maximum pixel area of 555. The pixel area of all valid 
objects were recorded and converted to a radius.  
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Hydrophone Measurements to Study Acoustic Behavior. A needle hydrophone 
was submerged in a glass test tube filled with 50 mL Milli-Q filtered water degassed 
overnight in a vacuum chamber. The radial position of the hydrophone was 
approximately halfway between the centerline of the vessel and the vessel wall, in 
order to minimize cavitation damage to the hydrophone. The height of the 
hydrophone along the z-axis was controlled by an adjustable mount. The 
hydrophone was connected to an oscilloscope (DSO1012A, Agilent Technologies, 
Santa Clara, CA). The ultrasonic horn was operated at 20% amplitude setting at 
pulses of 500 ms; the probe height was set at 60 mm. Waveform data for horn 
pulses were recorded along the z-axis of the vessel at 2 mm increments from 0-30 
mm, with 0 mm being the bottom of the vessel. Pressure magnitudes were 
calculated as running averages of peak-to-peak voltages (Vpp) from the waveform 
data. Vpp measurements were taken for two different test tube boundary conditions: 
(1) vessel exposed to air and (2) vessel exposed to large water bath. Vpp 
measurements for each condition were normalized by the highest value at that 
condition to calculate a relative pressure amplitude at each height along the vessel.  
 
Results 
Streak Photography to Study Flow Behavior. Figure 3.2B displays representative 
images of flow behavior in the ROI over one pulse cycle as well as the pulse 
waveform and the flow score of each image. These images reveal that acoustic 
streaming generated by the ultrasonic horn results in coherent, vortical structures 
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that are punctuated by regions of apparently turbulent behavior. Flow structures 
are similar from pulse to pulse. Fluid flow is generated from the tip of the horn, 
downwards towards the bottom of the vessel. When the flowing fluid reaches the 
bottom of the vessel, the fluid is redirected along the bottom and up the side walls, 
resulting in recirculation into the bulk of the liquid. These observations are 
consistent with flow patterns observed in other ultrasonic horn systems. Flow score 
slightly lags the pulse waveform; the horn needs to overcome inertial and viscous 
forces before axial streaming velocity reaches a maximum.  
Figure 3.3 displays the average flow score in the ROI over 10 sec of 
ultrasound dosage calculated at each combination of pulse height and amplitude 
setting. Flow score increases non-linearly with increasing amplitude setting and 
decreasing probe height. Amplitude setting is related to acoustic power, with a 
higher amplitude setting resulting in higher applied acoustic power. As probe 
height decreases, the distance between the streaming source and the ROI 
decreases. The increase in flow score observed for lower probe heights indicates 
that the magnitude of streaming effects is higher closer to the acoustic source and 
attenuates as the distance from the source is increased. 
 
High Speed Photography to Study Cavitation Behavior. Figure 3.4, A-E, displays 
representative images of cavitation behavior at each amplitude setting tested. 
Bubble radii data, displayed in Figure 3.4F, show that for all amplitude settings 
tested, except for 20%, bubbles larger than 80 µm exist. For increasing amplitude 
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setting, the amount of bubbles between 50-80 µm increases; however, at higher 
amplitude settings, bubbles greater than 80 µm in diameter are less common than 
at lower amplitude settings. This observation suggests that at higher amplitude 
settings (i.e. higher driving pressures), bubbles become non-spherical, and their 
growth is limited by shape instabilities. Figure 3.4G displays bubble density as a 
function of horn amplitude setting. Bubble density increases with increasing 
amplitude setting up until a threshold amplitude setting around 80%. These data 
taken together suggest that cavitation behavior is dominated by large amounts of 
smaller bubbles rather than the presence of large bubbles. 
 
Hydrophone Measurements to Study Acoustic Behavior. Pressure amplitudes 
along the height of the test vessel at 2 different probe heights are displayed in 
Figure 3.5 for a test vessel with walls exposed to air and with walls submerged in 
a large water bath. In all cases, standing waves are observed with nodal spacing 
of about 17 mm consistent with the expected wavelength of 40 kHz in bubbly water 
of modest gas volume fraction. The spatial distribution of the sound field varies 
with boundary condition and horn height. The behavior of the pressure amplitude 
between z = 0-5 mm, where the tablet initially resides differs for the two cases. 
When the vessel walls are submerged in a water bath, the pressure amplitude in 
the boundary/tablet region is lower than the pressure amplitude in the air surround 
condition. Pressure amplitudes showed a strong variation with probe height as 
resonances are achieved at periodic values of probe height. The bottom of the 
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vessel in the air surround condition, for both probe heights, acted as an active 
surface with high acoustic pressure. 
 
Effect of System Parameters on Breakdown of and Drug Release from Tablets 
Materials and Methods 
Materials. Ethanol (200 proof) was obtained from Sigma Aldrich (St. Louis, MO). 
USP Prednisone reference powder (Lot: O0G356) and USP Prednisone Lot P 
Performance Verification Tablets (PVT) (Lot: R031Y1) were obtained from Fisher 
Scientific. 
 
Continuous Sampling System Lag Time. The system was completely primed with 
20% ethanol solution. Absorbance measurements were taken at 285 nm for 5 
minutes. After 5 minutes, the pump was stopped, and the sampling tube was 
transferred into a test tube containing 50 mL 0.2 mg/mL Prednisone in 20% 
ethanol. The pump and absorbance measurements were immediately restarted 
after the sampling tube was transferred. Absorbance was measured for 10 min.  
 
Prednisone Standard Curve. A stock solution of 0.2 mg/mL prednisone was 
prepared in 20% ethanol by adding 20 mg prednisone to 100 mL 20% ethanol and 
stirring overnight. Dilutions of prednisone in 20% ethanol were prepared from the 
stock solution at 0.05 mg/mL, 0.1 mg/mL, 0.15 mg/mL, and 0.2 mg/mL. The 
continuous sampling system was set up without the cannula and in-line filters. The 
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tubing was fully primed with 0.00 mg/mL prednisone in 20% ethanol. The 
Spectromax M5 spectrophotometer was set to measure absorbance at 285 nm 
every 5 seconds for 30 minutes. 5 mL of 0.00 mg/mL prednisone was pumped 
through the sampling system. Next, the sampling tube was moved from the 0.00 
mg/mL prednisone solution into a 5 mL Eppendorf tube containing 5.0 mL of 0.05 
mg/mL prednisone. After the entire volume of this dilution was sampled, the 
sampling tube was transferred to an Eppendorf tube containing the next highest 
concentration of prednisone. This process was repeated until all solutions were 
sampled.  
 
Stability of Prednisone in Presence of Ultrasound. A solution of 0.2 mg/mL 
prednisone in 20% ethanol was prepared by adding 20 mg of prednisone to 100 
mL 20% ethanol and stirring overnight. The ultrasonic agitation mediated setup 
described above was used.  The system was primed with 50 mL prednisone 
solution. Sonication was applied at 50% amplitude setting and 35 mm probe height 
for 1 hour. Absorbance was measured over this time. 
 
Effect of Amplitude Setting and Probe Height on Drug Release. Drug release 
testing of tablet samples was performed using the experimental setup described 
above. Prednisone tablets dissolved in 20% ethanol solution were used as a model 
system. 53 mL 20% ethanol solution was dispensed into the test vessel. The 
system was primed with media for 5 min. After priming, absorbance measurements 
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were taken for 80 sec to establish a baseline. A prednisone tablet was then 
inserted into the vessel and the horn was turned on. Ultrasonic agitation was 
applied to the test media for up to 3600 sec. At the end of the test, ultrasonic 
agitation was applied to the dissolved tablet solution for 5 min at 50% amplitude 
setting to ensure complete drug release. The horn was shut off, and absorbance 
measurements continued for 6 minutes. The system was flushed with fresh 20% 
ethanol solution for 10 min and dried out using air after each test. Three tablets 
were tested at each parameter configuration. Drug release testing was performed 
for amplitude settings of 30%, 35%, 40%, and 45% at probe heights of 35 mm, 45 
mm, and 55 mm. 
 
Effect of Vessel Boundary Condition on Drug Release. Drug release testing was 
performed as described in the previous section. The experimental setup consisted 
of a glass test tube exposed to the two boundary conditions described above, but 
was otherwise identical to the setup described in section 2.1. Drug release tests 
were performed at an amplitude setting and probe height of 30% and 60 mm, 
respectively. Three prednisone tablets were dissolved at each boundary condition. 
 
Release Data Processing and Analysis. Absorbance data from drug release testing 
was processed in MatLab (MathWorks, Natick, MA) prior to data analysis. 
Background absorbance of each test was calculated by averaging the first 80 sec 
of absorbance measurements from a test. Absorbance at complete tablet 
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dissolution was calculated by averaging the last 80 sec of absorbance 
measurements from a test. The determined lag time was used to correct for the 
start and stop time of the test. Absorbance values for a test were background 
subtracted and normalized to absorbance at complete dissolution to yield fraction 
dissolved. 
Dissolution efficiency was used as a general rate parameter to compare 
drug release curves across critical system parameters. Dissolution efficiency was 
calculated using equation 3.4; the trapezoidal method was used to calculate the 
area under the fraction dissolved vs time curve. Dissolution efficiency was 
determined between 0-180,000 sec for all tests. 
 
Results 
Sampling System Characterization. Figure 3.6 shows how absorbance changes 
over time when the sampling input is changed from a 20% ethanol solution to 0.2 
mg/mL Prednisone in 20% ethanol. A maximum absorbance value of 20% ethanol 
at 270 nm was determined by calculating the standard deviation of absorbance 
over 5 minutes and adding 1.5x of this value to the average absorbance calculated 
over this time period. The lag time of the sampling system was defined as the time-
point immediately preceding the time-point in which the absorbance exceeds this 
maximum value. The lag of the system was determined to be 100 sec.  
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Prednisone Characterization. Figure 3.7 displays the absorbance measurements 
of a 0.2 mg/mL prednisone solution over 1 hr exposure to ultrasonic agitation at 
50% amplitude setting and 35 mm probe height. Absorbance is constant for 1 hr 
exposure to ultrasound at these settings. 
 Figure 3.8 shows these average absorbance values as a function of solution 
concentration. The absorbance of prednisone solutions increases linearly between 
concentrations of 0.0 mg/mL – 0.2 mg/mL. This linear relationship allows for the 
concentration of a solution of prednisone to be calculated from an absorbance 
measurement over this range. 
 
Effect of Amplitude Setting and Probe Height on Drug Release. Figure 3.9 displays 
drug release profiles of USP PVT prednisone tablets in 20% ethanol solution 
dissolved via ultrasonic agitation at 12 different combinations of amplitude setting 
and probe height. Drug release fell into three unique regimes dependent of 
amplitude setting and probe height. At an amplitude setting of 30%, fraction 
dissolved at all probe heights steadily increased over 3600 sec, and the maximum 
fraction dissolved after 3600 sec was 0.25 at a probe height of 35 mm. At amplitude 
settings of 40% and greater, fraction dissolved at all probe heights rapidly 
increased and approached 1.0 within 600 sec after the onset of ultrasonic agitation. 
At an amplitude setting of 35%, fraction dissolved after 3600 sec and the shape of 
drug release profiles strongly varied with probe height.  
A dissolution efficiency was calculated for drug release profiles generated 
45 
 
 
at each parameter set tested, shown in Figure 3.10. Dissolution efficiency 
increased with increasing amplitude setting and decreasing probe height. At an 
amplitude setting of 30%, dissolution efficiencies were less than 12%. At amplitude 
settings of 40% and higher, dissolution efficiencies were all greater than 85%. 
Achievable dissolution efficiencies widely varied at 35% amplitude setting for all 
probe heights. Percent coefficient of variations between trials at each probe height 
at ≤30% amplitude setting and ≥40% amplitude setting were as low as 4.5% and 
0.3%, respectively. Percent coefficient of variation between trials for each probe 
height at 35% amplitude setting were greater than 15%. 
 
Effect of Vessel Boundary Condition on Drug Release. Dissolution efficiencies for 
tablets dissolved in vessels with walls exposed to air and submerged in water are 
displayed in Figure 3.11. The difference in dissolution efficiencies calculated for 
each boundary condition was not statistically significant. 
 
Discussion 
The ultrasonic agitation mediated test does not aim to replicate or mimic the 
physiological environment experienced by tablets, a key consideration of all 
traditionally defined and official dissolution apparati. In light of this, this method is 
not presented as a replacement to official dissolution testing. Drug release data 
collected from any well characterized and discriminatory methods can provide 
fundamental information on dosage form composition. By removing the constraint 
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of in vivo predictability, new approaches to drug release testing can be designed 
to meet specific needs that current methods do not accommodate well. The 
method presented here can serve as a supplementary approach to traditional tests 
to provide rapid and low-cost screening of relative differences in dosage form 
composition. For example, a small volume test using commercially available 
equipment has potential applications in the study of drug release properties from 
low-dose and novel solid dosage forms as well as reduced cost and portable 
release testing for post-manufacturing tablet quality screening, a current need in 
low- and middle-income countries. 
Prednisone tablets were chosen for this study because they are used as 
Performance Verification Testing tablets for USP apparatuses; their drug release 
behavior in those systems is very well characterized. Prednisone tablets are 
immediate release, disintegrating, and effervescent. These types of tablets swell 
and break apart into smaller granules when exposed to aqueous media. In 
traditional dissolution apparatuses, drug release occurs primarily from these 
granules in the presence of convective flow. Ultrasonic agitation can enhance the 
drug release process by intensifying tablet disintegration by two potential 
mechanisms. First, inertial and stable cavitation events occurring near the outer 
surface of the tablet result in microjetting that can break-apart fragments from the 
tablet surface. Second, ultrasonic agitation can result in cavitation events owing to 
the gas trapped in the tablets, breaking the tablet into smaller fragments from the 
inside-out near the surface.  
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Drug release behavior from prednisone tablets in 20% ethanol solution was 
observed to fall into three different regimes that were dependent on amplitude 
setting and probe height. Each regime is characterized by a unique interplay 
between the tablet disintegration process and the convective fluid flow in the test 
vessel. In the fast regime, the tablet is rapidly disintegrated into smaller fragments 
over approximately the first 30 sec of ultrasonic agitation. The convective fluid flow 
in this regime is strong enough to cause circulation of tablet fragments throughout 
the vessel. All tablet fragments undergo diffusive mass removal by convective flow 
and further fragmentation by inertial cavitation events. In the slow regime, tablet 
disintegration occurs over approximately 200 sec of ultrasonic agitation; this 
process is dominated by modest fluid penetration into the tablet and cavitation. 
The convective flow in this regime is not strong enough to cause circulation of 
tablet fragments throughout the vessel, and tablet fragments end up spread out 
along the bottom of the vessel. Undissolved fragments on the top layer are the 
only fragments to undergo diffusive mass removal due to convective fluid flow and 
inertial cavitation events. In the transition regime, tablet disintegration occurs 
between 30-200 sec depending on the flow and cavitation behavior. The onset, 
extent, and duration of circulation of tablet fragments in this regime is stochastic, 
so the amount of fragments exposed to convective flow and inertial cavitation 
differs from run-to-run for a given parameter set. The dissolution efficiencies 
produced in each regime reflect these observations. For the slow and fast regimes, 
dissolution efficiencies fall in distinct ranges, and variability between trials is low. 
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In the transition regime, the range of achievable dissolution efficiencies is much 
wider, and variability between trials is high.  
The most striking feature of the measurements presented is the threshold 
dependent behavior characterizing the transition from slow to fast release. A 
traditional acoustic interpretation would indicate that threshold is primarily 
dominated by the onset of inertial cavitation; however, the described observations 
are more complicated. Visual observations reveal the primary difference between 
slow and fast release regimes to be the rapid, near-turbulent convective transport 
of fragments away from the bottom of the vessel into the bulk of the container. This 
behavior and the similar increases in dissolution efficiency (Figure 3.10) and flow 
score (Figure 3.3) with amplitude setting and probe height suggest that acoustic 
streaming velocity mainly controls the slow-fast transition – axial velocity in the 
tablet region of the vessel as measured from the horn tip directly interacting with 
the cavitation-fragmented tablet, at a given combination of amplitude setting and 
probe height, can result in advection of fragments up into the volume of the vessel 
exposing fragments to higher levels of cavitation and flow. This proposed 
mechanism is the most comprehensive assessment that can be made with the 
experimental results and observations presented here. Quantitative and spatial 
measurements of cavitation and axial streaming are needed to further elucidate 
the mechanism of the slow/fast threshold release behavior. 
 Interactions between drug, tablet formulation, and test media also 
determine drug release behavior by affecting the rate and extent of tablet 
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disintegration and drug diffusion. The reduced volume nature of the ultrasonic 
agitation drug release method may necessitate the use of non-aqueous media to 
ensure complete solubility; in these tests, a 20% ethanol solution was needed for 
complete solubility of prednisone. Full characterization of the ultrasonic agitation 
mediated drug release test will involve further interrogation of both the acoustic 
properties of the system and the chemical properties of the dissolving species on 
the tablet disintegration and drug diffusion processes. The potential impact of 
temperature on the system also needs to be addressed. Temperature of the test 
media increased by 4-6 °C during all tests dependent on the amplitude setting and 
probe height; the temperature increase at any given parameter set was consistent 
between tests. One question of interest is how the application of ultrasonic 
agitation affects fracture and diffusion behavior of dissolving species. Decoupling 
and understanding individual contributions from each of these processes proves 
to be a challenging task from an experimental perspective. Mathematical modeling 
can provide a framework for exploring these phenomena individually, as well as 
their interplay. These approaches are the focus of Chapter 4. 
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Figure 3.1. Schematic of Ultrasonic Agitation Mediated Test with Continuous 
Sampling System.  
Schematic of experimental setup used for ultrasonic mediated drug release testing. 
Dissolved tablet solution is sampled continuously in closed-loop system.  
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Figure 3.2. Streak Photography Setup. 
(A) Schematic of experimental setup used for streak photography experiments. 
Please note that the camera is positioned perpendicularly to the illuminated plain; 
the image is not to scale. (B) Streak photography images over 1 pulse cycle. The 
pulse waveform and flow score is displayed for each image over the pulse cycle. 
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Camera characteristics Value 
Focal Length 200 mm 
Resolution 256 x 224 pixels 
Acquisition Rate 100,000 fps 
Shutter speed 1/253,000 sec 
Table 3.1. High Speed Photography Image Acquisition Parameters.  
Image acquisition parameters of FASTCAM SA5 mounted with 200 mm Nikon 
objective. 
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Figure 3.3. Characterization of Bulk Flow. 
Flow Score as a function of amplitude setting for probe heights of 40 mm (squares), 
50 mm (circles), and 60 mm (triangles). 
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Figure 3.4. Characterization of Cavitation Activity Beneath Ultrasonic Horn. 
Bubble formation and cloud behavior directly under the ultrasonic horn at 
amplitude settings of 20%, 40%, 60%, 80%, and 100% (A-E). Histogram of bubble 
radii formed over 10 ms at amplitude settings of 20-100% (F). Bubble density at 
each amplitude setting (G). 
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Figure 3.5. Characterization of Acoustic Field. 
(A) Peak-to-peak voltage measured as a function of height from the bottom of the 
vessel at 50 mm (blue) and 60 mm (red) probe heights for 2 different boundary 
conditions: air (solid lines), water (dashed lines). 
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Figure 3.6. Determination of System Lag Time. 
 The amount of time until a sampled aliquot of liquid is detected in the flow-cell was 
calculated by determining the time point preceding which the absorbance 
increases past a threshold of the mean baseline + 3 * standard deviation. 
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Figure 3.7. Measured Prednisone Absorbance During Exposure to Extended 
Ultrasonic Agitation. 
Absorbance of 0.2 mg/mL prednisone over 1 hr exposure to ultrasound at 50% 
amplitude setting and 35 mm probe height. Absorbance does not change over this 
time period. 
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Figure 3.8. Prednisone Standard Curve. 
Absorbance of prednisone solutions of concentration 0.00, 0.15, 0.10, 0.15, and 
0.20 mg/mL at 285 nm, R2 =0.9983. 
  
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
0 0.05 0.1 0.15 0.2
A
b
so
rb
an
ce
Concentration (mg/mL)
59 
 
 
 
Figure 3.9. Prednisone Release Across Probe Height and Amplitude Setting 
Parameter Space. 
Drug release curves from prednisone tablets at different combinations of amplitude 
setting and probe height for a fixed acoustic dosage (1 Hz, 50% duty cycle). Three 
tablets were dissolved at each combination of amplitude setting and probe height. 
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Figure 3.10. Dissolution Efficiency as a Function of Amplitude Setting and 
Probe Height. 
Dissolution efficiency as a function of amplitude setting at probe heights of 35 mm 
(squares), 45 mm (circles), and 55 mm (triangles). Data plotted as mean ± 
standard deviation (n=3). 
  
61 
 
 
 
Figure 3.11. The Effect of Boundary Condition on Dissolution Efficiency. 
Dissolution efficiency at 60 mm probe height and 30% amplitude setting for air and 
water boundary conditions. 
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EXPLORING THE INTERPLAY BETWEEN FRACTURE AND DIFFUSION 
DURING SOLID DISSOLUTION VIA A NOVEL MATHEMATICAL MODEL 
 
The previous chapter employed a range of experimental techniques and 
approaches to study and understand the hydro-acoustic environment and the drug 
release process over a range of critical system parameters. Results and 
observations from these experiments demonstrated convective flow generated 
from the horn, in combination with cavitation events, determined the overall drug 
release process. Drug release from tablets occurs through 2 mechanisms – 
breakdown of the tablet and diffusion from tablet fragments.  The dynamics of both 
of these mechanisms and their relative contributions to the overall drug release 
process appear to be heavily dependent on the hydro-acoustic environment in the 
reactor. This relationship is complex and difficult to probe experimentally.  
Mathematical modeling can make problems like this more tractable. By 
breaking a problem down to first principles and stripping away unnecessary 
complexities, models can provide insight into systems fundamentals and inform 
hypotheses. To this end, a partial differential equation model of solid dissolution 
was developed to explore the 2 constituent mechanisms of surface area 
dependent diffusion and physical fracture of solid particles. The model was used 
to study the individual effects of each mechanism on the dissolution process, a 
task that proves extremely difficult experimentally. The model was then fit to 
experimental drug release data from the ultrasonic agitation mediated test, and the 
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dissolution process was studied as a function of input ultrasound power. This 
model will inform future experimental work towards understanding and optimizing 
ultrasonic agitation mediated drug release. 
 
Background 
Modeling Diffusion from Tablets 
The early mathematical foundations of dissolution are based on the work of 
Noyes and Whitney, who described dissolution as a diffusive process, proportional 
to the difference between the saturation concentration of the solute in the solvent, 
or the solubility, and the bulk concentration of the solute in the solvent13. This 
concentration gradient approach, inspired by Fick’s first law, has continued to 
influence diffusion-based dissolution modelling39. Brunner and Tolloczko 
determined that the rate of mass removal is proportional to the surface area of the 
dissolving particle, adding an important new parameter to this diffusion-based 
model of dissolution15. Nernst and Brunner built upon their predecessors by 
explicitly describing dissolution as the diffusion of solute molecules across a 
boundary layer of unstirred solvent surrounding each dissolving particle, noting 
that the rate of diffusion is inversely proportional to the width of this unstirred 
boundary layer, and that the width is affected by the flow properties of the fluid 
around it17,105. Finally, Hixson and Crowell were the first to address the dynamic 
nature of surface area during the dissolution process. Where previous models 
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treated surface area as a constant, this approach was the first to address that the 
surface area of a dissolving particle changes as mass is removed, allowing the 
modelling of dissolving particles over longer time periods16. The end result of these 
innovations is equation (1) below, which we will refer to as the modified Nernst-
Brunner equation, 
(Eq. 4.1)     
𝑑𝑚
𝑑𝑡
=⁡−
𝐷𝑆(𝑡)
𝐿
(𝐶𝑠 − ⁡𝐶(𝑡)) 
where m is the total dissolved mass, S is the total exposed surface area of the 
dissolving particle at time t, D is the diffusion coefficient of the solute in the solvent, 
L is the thickness of the boundary layer of unstirred solvent surrounding the 
particle, Cs is the solubility limit of the solute in the solvent, and C(t) is the mass 
concentration of the dissolved species at time t. 
 These first order models based off of Fick’s first law were first to applied 
drug dissolution studies by Gibaldi and Feldman in 1967 and Wagner in 1969106,107. 
The first models to directly consider drug release were devised by Higuchi in the 
early 1960s to describe release of water soluble and low-soluble drug from semi-
solid and solid matrices59,108. These models have been applied to release from 
homogeneous and heterogeneous matrices in planar and spherical geometries. 
Several other empirical and semi-empirical models have been developed to 
describe release from various modified and extended release dosage forms64,109. 
These models are detailed in Table 4.1. 
 All of these modeling approaches treat dissolution as a monolithic process, 
neglecting any physical change in the dissolving species, such as disintegration. 
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Some consider the presence of multiple particles of identical properties110. Studies 
exploring the dissolution of powders have demonstrated the effects of starting 
particle size distribution on the evolution and overall dissolution kinetics of that 
system111. These studies only consider particle size distributions as a starting point 
and do not consider changes in relative distribution of particle sizes.  
Dissolution of many solid oral dosage forms is known to be a complex 
process in which the physical structure readily dissociates to increase the surface 
area available from which the drug can dissolve. The mechanism and extent to 
which this is occurs is known to greatly affect the in vivo performance of drugs. 
Important information captured in particle size distributions throughout the process 
could be neglected in models that only focus on bulk behavior.  
 
Mathematical Model of Solid Diffusion as Controlled by Fracture and Dissolution 
Events 
Our model takes into account the two physical processes contributing to 
solid dissolution in a liquid solvent, represented by two sub-models: the surface-
area-dependent, concentration gradient-based diffusive mass removal and the 
fragmentation of all undissolved particles. Both processes can be driven by an 
external perturbing force, examples of which include ultrasonic agitation, 
mechanical agitation, and solvent flow. 
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Diffusion Model 
 The model idealizes each particle as a mass of arbitrary shape submerged 
in a liquid solvent. Mass is constantly being removed by diffusion from all surfaces 
of the solute exposed to solvent. The rate of this diffusive mass removal is 
described by the Hixon-Crowell equation (Eq. 4.1). The model assumes that the 
agitated liquid is well-mixed, as the dissolved solute concentration is calculated as 
an average value for the entire fluid volume. Particle sizes are tracked as a 
distribution N(V,t) of the number of undissolved particles of volume, V, at time, t, 
throughout the entire process.  
 The primary governing equation is  
(Eq. 4.2)     
𝜕𝑁(𝑉,𝑡)
𝜕𝑡
+⁡
𝜕
𝜕𝑉
(𝑅(𝑉, 𝑡)𝑁(𝑉, 𝑡)) = 0 
where R(V) is a function based on the Nernst-Brunner equation describing the 
volume removal rate from all particle surface area over time of the form 
(Eq. 4.3)     𝑅(𝑉, 𝑡) = ⁡−𝑘𝑐 (
𝐶𝑠
𝜌
−⁡
𝑉𝑜−⁡∫ 𝑁(𝑉,𝑡)𝑉(𝑡)𝑑𝑉
𝑉𝑜
𝑉𝑚𝑖𝑛
𝑉𝑐𝑜𝑛𝑡
) ∗ 𝑆(𝑉) 
Where kc is the mass transfer coefficient for the solute in the solvent, Cs is the 
maximum solubility of the solute in the solvent, ρ is the density of the solute, Vmin 
is the minimum particle volume under consideration, V0 is the original particle 
volume, Vcont is the container volume, and S(V) describes the surface area of a 
particle of volume V. S(V) is of the form 
(Eq. 4.4)     𝑆(𝑉) = ⁡𝜅𝑉2/3 
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Where κ is a constant dependent on the chosen particle geometry; particles are 
assumed to be spherical, so 
(Eq. 4.5)     𝜅 = ⁡∛(36𝜋) 
 This model was compared against the analytically-solved Nernst-Brunner 
equation as a validation step. These results are displayed in Figure 4.1. Given the 
same initial conditions and parameters, the diffusion model described above 
predicted volume loss over time for a single dissolving particle to within 1.25 X 10-
5
 % of the Nernst-Brunner equation. 
 
Fragmentation Model 
 The fragmentation model considers how particles break apart during the 
dissolution process. A fragmentation event of a single particle involves the 
breakdown of the particle into smaller particles of varying sizes. Each 
fragmentation event is defined by 2 mathematical constructs, the fragmentation 
rate and the transition function. The volume-dependent fragmentation rate 
represents the rate at which each undissolved particle of volume V fragments into 
new smaller particles. The transition function defines the distribution of particles of 
volumes V created in each fragmentation event from a particle of original volume 
Vi. The evolution of the particle-size distribution function N(V,t) is described by the 
integral equation 
(Eq. 4.6)    
𝜕𝑁(𝑉,𝑡)
𝜕𝑡
= ∫ [𝑔(𝑉𝑖) ∗ 𝑓(𝑉𝑖 → 𝑉)
𝑉0
𝑉
∗ 𝑁(𝑉𝑖, 𝑡)]𝑑𝑉𝑖 − 𝑔(𝑉) ∗ 𝑁(𝑉, 𝑡) 
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Where V0 is the maximum particle volume at time t = 0, f(Vi  V) is the transition 
function, and g(V) is the fragmentation rate.  
 The transition function is a distribution over all possible particle volumes 
less than that of the original particle and is normalized to the original particle 
volume in each fragmentation event and is visualized in Figure 4.2. In this model, 
the normalized lognormal distribution was found to capture the widest range of 
experimental regimes, so the transition function takes the form 
(Eq. 4.7)     𝑓(𝑉𝑖𝑛 →⁡𝑉𝑜𝑢𝑡) = ⁡
𝐵
𝑉𝑜𝑢𝑡
exp⁡((
𝑉−⁡𝜇
√(2)𝜎
)
2
) 
(Eq. 4.8)     𝑉 = ⁡
(𝑙𝑜𝑔10𝑉𝑜𝑢𝑡−⁡𝑙𝑜𝑔10𝑉𝑚𝑖𝑛)
(𝑙𝑜𝑔10𝑉𝑖𝑛−⁡𝑙𝑜𝑔10𝑉𝑚𝑖𝑛)
 
Where Vin is the volume of the particle undergoing fragmentation, Vout is the volume 
of the new particle created by the fragmentation event, Vmin is the minimum particle 
size being considered, B is a normalization constant, and µ and σ are the mean 
and standard deviation of the normalized base-10 logarithm of particle volume, 
respectively. The term µ is subsequently referred to as the scale parameter. The 
normalization constant, B, was included to ensure volume conservation during 
each fragmentation event, calculated such that 
(Eq. 4.9)     ∫ 𝑓(𝑉𝑖𝑛 →⁡𝑉𝑜𝑢𝑡)⁡𝑑𝑉𝑜𝑢𝑡 =⁡𝑉𝑖𝑛
𝑉𝑜𝑢𝑡
𝑉𝑚𝑖𝑛
 
 The volume-dependent fragmentation rate is defined as 
(Eq. 4.10)     𝑔(𝑉) = ⁡𝑔0𝐻(𝑉 − 𝑉𝑚𝑓) 
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Where g0 is the constant fragmentation rate, Vmf is the minimum fragmenting 
volume, H(x) is the Heaviside function. Vmf is the smallest volume at which 
fragmentation still occurs; at volumes less than Vmf particles only undergo diffusive 
mass removal until all of their mass is dissolved. This minimum fracture volume is 
set to minimize round-off error associated with the fragmentation of particles close 
to the minimum simulated particle size.  
 
Combined Model 
 The diffusion model (Eq. 4.2) and the fracture model (Eq. 4.6) are combined 
to obtain the single governing equation 
(Eq. 4.11)     
𝜕𝑁(𝑉,𝑡)
𝜕𝑇
=⁡−
𝜕
𝜕𝑉
(𝑅(𝑉, 𝑡)𝑁(𝑉, 𝑡)) +⁡∫ (𝑔(𝑉𝑖)𝑓(𝑉𝑖 → 𝑉)𝑁(𝑉𝑖, 𝑡)𝑑𝑉𝑖 −
𝑉0
𝑉
𝑔(𝑉)𝑁(𝑉, 𝑡) 
 
Computational Approach 
 The main governing equation, Eq. 4.11, is simulated using a 4th-order 
explicit Runge-Kutta finite difference scheme. All simulations were performed with 
100 discretized volume points, half of which are spaced linearly among the top 
90% of particle volumes and half of which are arranged logarithmically across the 
remaining orders of magnitude down to the smallest simulated particle volume. 
This framework was implemented in MATLAB (Mathworks, Natick, MA). 
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The Dynamic Interplay of the Total Dissolution Process 
 All simulations described in this section were performed with the parameters 
listed in Table 4.2, unless otherwise stated. 
 
Model Outputs 
 Figure 4.3 and 4.4 represent a generic solid dissolution process simulated 
by our model and display the process as a time course and the distribution of 
particle sizes, respectively. Total particle number, percent initial volume dissolved, 
and total surface area are plotted as a function of time. Number of particles of 
volume V, total volume of particles of volume V, and total surface area of particles 
of volume V are plotted as a function of the base-10 logarithm of particles of volume 
V.  
 Figure 4.3B plots the percent of initial volume dissolved, or total amount 
dissolved, as a function of time. This curve displays a sigmoidal shape, common 
of solid dissolution processes, and this shape is a direct result of the competing 
processes of fracture and diffusion. Total particle number, displayed in Figure 
4.3A, increases slowly initially as the fracture process begins. The total particle 
number then increases exponentially after a threshold number of particles is 
achieved. Particles continue to fracture until they reach the minimum fracturing 
diameter causing the rate of increase in particle number to decrease until total 
particle number reaches a maximum. As particles are fracturing, they are shrinking 
due to diffusive mass removal. This process also contributes to the decrease in 
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rate of particle number increase and is the sole driver of the eventual decrease in 
particle number. The fracture and diffusion processes result in a similar overall 
behave in total surface area as a function of time. Total surface initially increases 
slowly as fracture begins. As existing particles begin to undergo fracture at a faster 
rate, the total surface area increases exponentially. Total surface area increases 
less rapidly, eventually peaks, and starts to decrease as particles become too 
small to fracture and diffusive mass removal becomes the dominant process. 
 Considering this process from a distribution standpoint – a perspective 
uniquely afforded by this modeling framework- displays a similar behavior across 
the 3 tracked variables, all shown in Figure 4.4. At the start of the process, the total 
volume is stored in 1 particle. Particles of smaller volumes are formed rapidly as 
the fracture process starts. Particles of the smallest tracked volume accumulate 
rapidly. Most particles have reached or are approaching this minimum particle size 
by 160 sec in this simulation, and magnitudes of the distributions decreases after 
this time as particles are completely removed by diffusive mass removal. 
 
Model Verification 
Diffusive mass removal only. In order to observe the specific effects of changes in 
diffusive mass removal kinetics on the overall dissolution process, all 
fragmentation was removed from the modelling framework. Figure 4.5 displays a 
parameter sweep over the mass transfer coefficient. Figure 4.5A shows that 
particle number does not change when no fragmentation occurs, as expected. As 
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the mass transfer coefficient is increased, the rate at which mass is removed from 
all particles at all surfaces exposed to the solvent increases, speeding up the 
overall dissolution process, as shown in Figure 4.5B. Particles decrease in size 
and surface area as mass is removed, as shown in Figure 4.5C where the surface 
area monotonically decreases in all cases. Overall, in the absence of 
fragmentation, the dissolution process occurs faster with increasing mass transfer 
coefficients.  
 
Fragmentation Only. In order to observe the specific effects of changes in 
fragmentation kinetics on the overall dissolution process, all diffusive mass 
removal was removed from the modeling framework. Figure 4.6 displays a 
parameter sweep over fragmentation rate. Figure 4.6B verifies that the percent of 
the initial volume dissolved does not change in the absence of diffusive mass 
removal, as expected. As the fragmentation rate is increased, particle number 
increases at an increasing rate until the maximum number of particles allowed by 
the minimum particle size is reached, as shown in Figure 4.6A. A similar response 
is observed for total surface area in the system, as shown in Figure 4.6C. Overall, 
in the absence of diffusive mass removal, fragmenting solids reach the maximum 
allowable total particle number and surface area faster with increasing 
fragmentation rate. 
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Examining the Effects of Each Constituent Process 
Diffusive Mass Removal. The mass transfer coefficient, kc, was varied between 
2.0x10-9 m/s – 4.5x10-9 m/s to assess the effects of diffusive mass removal on the 
overall dissolution process in the presence of constant fragmentation behavior. 
The results of this parameter sweep are displayed in Figure 4.7. The overall rate 
of the dissolution process as kc increases, as shown in Figure 4.7B, owing to an 
increase in the rate of diffusive mass removal. For all values of kc tested, both the 
total particle number and the total surface in the system over time increase rapidly, 
reach a maximum, then decrease, as shown in Figures 4.7C and 4.7C, 
respectively. The magnitude of both of these maximum values decreases with 
increasing kc. This behavior suggests that the higher rates of diffusive mass 
removal observed at higher values of kc result in quicker removal of smaller 
particles decreasing the amount of particles that build up as well as the total 
surface due to these particles. 
 
Fragmentation. The process of fragmentation, as considered here, is described by 
three main parameters. The fragmentation rate, g0, describes the rate at which 
each particle undergoes fragmentation events. Fragmentation events are 
described by the distribution of particles resulting from each event relative to the 
original particle size; this distribution is defined by a transition function. The 
transition function, is defined by a scale parameter, µ, which describes the size of 
the new particles from each fragmentation event relative to the original particle 
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size, and a logarithmic standard deviation, σ, which describes the width of the 
distribution and thus the range of particle sizes. 
 Figure 4.8 displays the model output for a sweep over fragmentation rate 
between 0.00 s-1 – 0.05 s-1 while all other parameters are held constant. The 
fraction of particles which fragment each second increases with increasing 
fragmentation rate. The effects of the fragmentation rate of the total particle 
number and total surface area over time are displayed in Figure 4.8A and 4.8C, 
respectively. As fragmentation rate increases, both total particle number and total 
surface area reach a higher maximum value, and this peak is reached more 
rapidly. Both of these phenomena have the effect of increasing the overall rate of 
dissolution, as shown in Figure 4.8B. 
 Figure 4.9 displays the model output for a sweep over the transition function 
scale parameter, µ, between 0.4 and 0.9 while all other parameters are held 
constant. The scale parameter defines the size of the new particles created in each 
fragment event, relative to the original particle, so larger values of µ result in larger 
average particle size created in each fragmentation event and overall less 
additional surface area compared to smaller values of µ. The effects of the 
transition function scale parameter on the total particle number and total surface 
area over time are displayed in Figure 4.9A and 4.9C, respectively. As the scale 
parameter increases, both total particle number and total surface area reach a 
lower maximum value and this peak is reached at a later time. Both of these 
phenomena have the effect of decreasing the overall rate of dissolution, as shown 
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in Figure 4.9B. Smaller values of µ result in more particles of smaller diameter 
formed, greatly increasing the surface area available for diffusion. 
Figure 4.10 displays the model output for a sweep over the normalized 
logarithmic standard deviation of the transition function, σ, between 0.01 and 0.1 
will all other parameter are held constant. This parameter defines the range of 
particle sizes produced about µ, so as σ is increased, a fracture event results in a 
larger range of particle sizes created. The effects of the transition function 
logarithmic standard deviation on the total particle number and total surface area 
over time are displayed in Figure 4.10A and 4.10C, respectively. As σ increases, 
both total particle number and total surface area reach a lower maximum value 
and this peak is reached at a later time. Both of these phenomena have the effect 
of decreasing the overall rate of dissolution, as shown in Figure 4.10B. More 
uniform distributions around µ, i.e. lower values of σ, result in larger amounts of 
surface area added due to a fragmentation event.  
 
The Effects of Ultrasound Power on the Breakdown and Release of Drug from 
Tablets 
Materials and Methods 
Materials. Amodiaquine dihydrochloride and eosin-y were purchased from Sigmal-
Aldrich (St. Louis, MO). Ultrapure water from a Milli-Q apparatus (18kΩ) was used. 
Amodiaquine tablets (Camosunate 300 mg, Batch: 1507232) were sourced from 
Accra, Ghana.  
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Release from Camosunate Amodiaquine Tablets. Amodiaquine tablets were 
dissolved via ultrasonic agitation in 50 mL ultrapure water. Probe height was fixed 
at 60 mm. Input powers ranged from 1.71 W, 3.95 W, and 5.45 W. Test media was 
sampled at 6-time-points between 6-12 minutes. The amount of amodiaquine 
assay in each sample was assessed using the Eosin-Y assay for amodiaquine 
detection. 
 
Experimental determination of kc. Amodiaquine tablets were dissolved using 
ultrasound as described over. The media was sampled at every 15 sec between 
0-45 sec. The tablet is still mostly one, non-disintegrated solid by this point. A 
straight line was fit to release data over this interval. The mass transfer coefficient 
was determined from this slope. 
 
Results 
Release curves and fitting to experimental data. The results of fitting the model to 
experiment data are shown in Figure 4.11. Values of µ and go at the 3 input powers 
were extracted from the fitted curves. These values and the experimentally 
determined mass transfer coefficients are plotted in Figure 4.12. 
 
Model parameterization. Three parameters were found to be essential to overall 
system behavior. When these parameters were fit to experimental data, the model 
was able to robustly reproduce the average behavior of the physical system. These 
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3 parameters are the mass transfer coefficient, kc, the fragmentation rate, g0, and 
the transition function scale parameter, µ. The following functional forms were 
developed: 
(Eq. 4.12)     𝑘𝑐(𝑃) = ⁡𝑞1𝑒
𝑞2𝑃 
(Eq. 4.13)     𝑔0(𝑃) = ⁡𝑞3(𝑒
𝑞4𝑃-1) 
(Eq. 4.14)     µ(𝑃) = ⁡𝑞5 +
(1 − 𝑞5)𝑒
𝑞6𝑃−𝑞7
1 + 𝑒𝑞6𝑃−𝑞7
⁄  
Where q1-q7 are positive fit parameters and P is the applied ultrasound power. 
 The mass transfer coefficient, kc, increases as the ultrasound power 
increases. The magnitude of convective flow increases with increasing input 
power. The fragmentation rate go increases exponentially as the ultrasound power 
increases. Finally, the transition function scale parameter, µ, increases with 
ultrasound power in a sigmoidal fashion. This sigmoidal shape suggests that 
fragmentation events, as modelled, here can be divided into large and small 
particle regimes. The ultrasound fit parameters are displayed in Table 4.3. 
 
The Influence of Ultrasound on Solid Dissolution. Ultrasound affects both diffusion 
and fragmentation, as detailed in Eq. 4.12-4.13. The mass transfer coefficient 
increases with increasing ultrasound power resulting in an increase in the rate of 
diffusive mass removal. The fragmentation rate also increases with increasing 
ultrasound power resulting increase in surface area available for diffusion. Both of 
these relationships increase the overall rate of the dissolution process. The 
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transition function scale parameter also increases with increasing ultrasound 
power resulting in a decrease in surface area available surface after a 
fragmentation event; increases in µ decrease the rate of the dissolution process. 
 Figure 4.13 displays simulated dissolution processes over a range of 
applied ultrasound powers of 2W-5W. Figure 4.13A displays total particle number 
over time at each applied power. The rate at which the maximum total particle 
number is reached increases with applied power, and the maximum total particle 
number increases with applied ultrasound power except at the highest applied 
power tested. This observation is thought to be due to the competing processes of 
diffusion and fragmentation. Total surface area in the system over time at each 
applied power is displayed in Figure 4.13C. The maximum total surface area 
increases with applied power and is highest at an applied power of 5W. Like total 
particle number, the rate at which this maximum surface area is reached also 
monotonically increases over the range of applied powers. Taken together, these 
observations suggest that the rapid increase in surface area at 5W greatly 
increases the rate of particle removal due to diffusion resulting in less particles 
being stored in the system at any given time. Figure 4.13B shows that the rate at 
which the dissolution process occurs also monotonically increases with applied 
power, further supporting the proposed interaction between diffusive mass 
removal and surface area increase due to fragmentation; in addition, the trends 
observed for increasing ultrasound power match those observed in Figure 3.9. 
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Discussion 
 The physical fragmentation and surface area dependent diffusive mass 
removal model of solid dissolution adds to the current dosage form dissolution 
literature by describing the time evolution of particle size distributions as dissolving 
particles. While surface-area dependent diffusion is required for mass removal and 
total dissolution of an object, the interplay between diffusion and physical 
fragmentation has profound effects on the resulting particle size distribution and 
the bulk dissolution rate. Understanding the fragmentation process is crucial in the 
case of solid dosage forms as this process is known to directly affect the levels of 
bioavailability of dosage form payload. 
 This model allowed for the decoupling and controlled analysis of the 
fragmentation and diffusion processes, a task that proves difficult experimentally. 
The model shows that the dissolution process is characterized by a critical point 
where total surface area in the system reaches a maximum, after a rapid initial 
increase, and begins to decrease as the addition of new surface area is matched 
and overtaken by surface area decreases due to diffusive shrinking and 
disappearance of dissolving particles. The faster this critical point is reached, the 
faster the overall dissolution process proceeds. Low fragmentation regimes, 
achieved here when go equals zero or at large values of µ, are the only exception 
to this observation as the initial rate of surface area increase is not able to 
overcome the decrease in surface area due to diffusive mass removal.  
 External agitation of the solvent containing the dissolving species affects 
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both constituent processes, and the effects of ultrasonic agitation on the aggregate 
dissolution process were studied. Ultrasound applied over a range of 2W-5W 
results in widely varying particle size distributions in terms of total particle number 
and surface area. The model captures overall trends in experimental drug release 
data due to ultrasonic agitation. Deviations of the model predictions from 
experimental data at lower time-points are at least partially due to low resolution 
of the method used in the measurement of dissolved drug amount. 
 The model makes a few important assumptions. First, the solution of the 
dissolving species is assumed to well-mixed, such that the concentration is 
homogeneous throughout the entire volume. The incorporation of spatial effects, 
including the tracking fluid flow and particle transport, would allow for removal of 
this assumption and allow for modeling of dissolution cases where heterogeneities 
in solute and particle distribution play a large role, such as drug release in the small 
intestine. Second, the normalized log-distribution was found to be the most 
versatile transition function to describe fragmentation because particles over 
disparate orders of magnitude could be considered simultaneously. Experimental 
measurement of particle size distributions along the dissolution process and at 
different levels of agitation would provide more insight into the fragmentation 
process. The model also only considers diffusion processes rooted in first-order 
release kinetics. The ability to include different diffusion models would make the 
model more generally applicable. 
 The experimental drug release data used to parameterize the model are 
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from only one combination of API, dosage form, and solvent. This begs the 
question of whether these findings are applicable to other systems, such as co-
solvent and other non-aqueous solvent systems. Any differences could have 
implications in choice of solvent systems for drug release tests moving forward. 
 The previous 2 chapters described the characterization of the ultrasonic 
agitation mediated drug release test, focusing on the hydro-acoustic environment 
of system and the effects on the drug release process as well as more fundamental 
studies into fragmentation and diffusion-controlled dissolution. The next 2 chapters 
build off of the understanding gained from these studies and explore applications 
of the ultrasonic agitation mediated drug release test at 2 different stages of the 
drug development process. 
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Table 4.1. Drug Release Models. 
Common empirical and semi-emperical models for describing drug release from 
tablets. Zero order112, First Order106,107, Weibull113–115, Higuchi116–118, Hixon 
Crowell16, Korsmyer-Peppas119, Baker-Lonsdale120,121. 
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Figure 4.1. Comparison of Diffusion Model Numerical Solution to Nernst 
Brunner Solution. 
The numerical solution for percent original volume dissolved is compared to the 
analytical solution to the Nernst-Brunner equation. (B) The percent deviation of the 
numerical solution to the Nernst-Brunner solution is plotted vs time. Taken from 
Seager, Acevedo et al. 2018. 
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Table 4.2. Model Parameters Used in Simulations Examining Constituent 
Processes. 
Model parameters used in diffusion and fragmentation sweep simulations, unless 
otherwise noted. Taken from Seager, Acevedo et al. 2018. 
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Figure 4.2. Overview of the Transition Function. 
(A) A continuous transition function displaying the range of particle volumes, Vout, 
generated from a fracture event on particle Vin. (B) A visualization of a generalized 
transition function. Taken from Seager, Acevedo et al. 2018. 
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Figure 4.3. Example Model Output. 
An example of the model outputs of a sample dissolution process. The model 
tracks (A) total particle number, (B) percent initial volume dissolved, and (C) total 
surface area over time. The following parameters were used g0 = 5.46 x 10-9 s-1, µ 
= 9.83 x 10-1, and kc = 9.92 x 10-9 m/s. Taken from Seager, Acevedo et al. 2018.  
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Figure 4.4. Model output, time evolution. 
The time evolution as a function of the logarithm of particle of volume V of (A) total 
particle number, (B) total volume, and total surface area of a representative 
dissolution process, with g0 = 5.46 x 10-9 s-1, µ = 9.83 x 10-1, and kc = 9.92 x 10-9 
m/s. Taken from Seager, Acevedo et al. 2018. 
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Figure 4.5. Diffusive mass removal in the absence of fragmentation. 
(A) Total particle number, (B) percent of initial volume dissolved, and (C) total 
surface area over time for a simulated dissolution cases where the mass transfer 
coefficient varied from 2.0 x 10-9 m/s – 4.5 x 10-9 m/s and no fragmentation. Taken 
from Seager, Acevedo et al. 2018. 
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Figure 4.6. Fragmentation with no Diffusive Mass Removal. 
(A) Total particle number, (B) percent of initial volume dissolved, and (C) total 
surface area over time for a simulated dissolution cases where the fragmentation 
rate varied from 0.00 – 0.05 and no diffusive mass removal. Taken from Seager, 
Acevedo et al. 2018. 
  
91 
 
 
 
Figure 4.7. The Effect of Diffusion on the Dissolution Process. 
(A) Total particle number, (B) percent of initial volume dissolved, and (C) total 
surface area over time for a simulated dissolution cases where the mass transfer 
coefficient varied from 2.0 x 10-9 m/s – 4.5 x 10-9 m/s and all other parameters held 
at a non-zero constant. Taken from Seager, Acevedo et al. 2018. 
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Figure 4.8. The Effect of Fragmentation Rate on the Dissolution Process. 
(A) Total particle number, (B) percent of initial volume dissolved, and (C) total 
surface area over time for a simulated dissolution cases where the fragmentation 
rate varied from 0.00 – 0.05 and all other parameters held at a non-zero constant. 
Taken from Seager, Acevedo et al. 2018. 
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Figure 4.9. The Effect of Mean New Particle Size from Fragmentation on 
Dissolution Process. 
(A) Total particle number, (B) percent of initial volume dissolved, and (C) total 
surface area over time for a simulated dissolution cases where the transition 
function scale parameter varied from 0.4 – 0.9 and all other parameters held at a 
non-zero constant. Taken from Seager, Acevedo et al. 2018.  
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Figure 4.10. The Effect of Range of New Particle Size from Fragmentation on 
Dissolution Process. 
(A) Total particle number, (B) percent of initial volume dissolved, and (C) total 
surface area over time for a simulated dissolution cases where the transition 
function logarithmic standard deviation varied from 0.01 – 0.10 and all other 
parameters held at a non-zero constant. Taken from Seager, Acevedo et al. 2018.  
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Figure 4.11. Gradient-Descent Fit of Model to Experimental Release Data. 
The fragmentation rate, go, and the transitional function scale parameter, µ, were 
fit to dissolution experiments of Camosunate AQ experiments performed at 3 input 
powers – (A) 1.71 W, R2= 0.923, (B) 3.95 W, R2 = 0.966, and (C) 5.45 W, R2 = 
0.995. Taken from Seager, Acevedo et al. 2018. 
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Figure 4.12. Model Parameters as a Function of Ultrasound Power. 
(A) The mass transfer coefficient is plotted as a function of ultrasound power. 
Experimental data are plotted as mean ± standard deviation, n = 3. The data are 
fitted to the function defined in Eq. 4.12 (R2=0.998) to determine fit parameters q1-
q2. (B) The fragmentation rate plotted as a function of ultrasound power. Tested 
data points were determined from model fit to experimental data The fragmentation 
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rate was fitted to Eq. 4.13 (R2=0.999) to determine fit parameters q3-q4. (C) The 
transition function scale parameter plotted as a function of ultrasound power. 
Tested data points were determined from model fit to experimental data The 
transition function scale parameter was fitted to Eq. 4.14 (R2=1.000) to determine 
fit parameters q5-q7. Taken from Seager, Acevedo et al. 2018.  
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Table 4.3. Model Parameters Used in Ultrasound Power Sweep Simulations. 
Model parameters used in ultrasound power sweep. Fit parameters q1-q7 were 
determined by fitting model to experimental drug release data generated using the 
ultrasonic agitation mediated method. Taken from Seager, Acevedo et al. 2018.  
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Figure 4.13. The Effect of the Ultrasound Power on the Tablet Dissolution 
Process.  
(A) Total particle number, (B) percent of initial volume dissolved, and (C) total 
surface area over time for a simulated dissolution cases where ultrasound power 
ranged from 2W-5W. Taken from Seager, Acevedo et al. 2018. 
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CHAPTER 5: DRUG RELEASE TESTING DURING EARLY STAGE DOSAGE 
FORM DEVELOPMENT 
 
Formulation development starts early in the drug development process 
immediately after potential candidate molecules are identified. These preliminary 
formulations are focused on stabilizing the drug compound and act as first attempts 
to address solubility and absorption challenges. Drug release testing during this 
phase helps to assess the effectiveness of formulations towards these measures. 
Current methods of release testing require large amounts of sample, which can be 
costly during this stage as production methods are low-throughput. Small volume 
drug release methods would lower the amount of sample needed to test, lowering 
the cost per test and also increasing the screening capabilities of different test 
formulations. Groups developing novel dosage forms and dosage form 
manufacturing methods would also benefit from the decreased cost and time 
burden afforded by small volume drug release testing. 
The ultrasonic agitation mediated drug release method is applied to study 
drug release from composite polymeric and hydrogel microparticles. Droplet 
microfluidic technologies enable co-formulation of drug and polymer in 
monodisperse populations of microparticles with fine control of particle micro- and 
macrostructure122–125. These systems were used to study the effect of particle 
macrostructure as controlled by manufacturing parameters on drug release 
behavior using both mechanical and ultrasonic agitation methods. Release from 
101 
 
 
alginate microparticles containing nano-crystalline hydrophobic drug was studied 
using both USP and ultrasonic agitation methods. 
 
Background 
Drug-Loaded Composite Microparticles 
The first step of the dosage form manufacturing process is the crystallization 
of API. Crystal form dictates crucial physiochemical properties and 
pharmacokinetic attributes; different crystal forms of the same API, or polymorphs, 
can display widely different stability, solubility, and dissolution rates126. 
Crystallization is a complex process that proves very difficult to control, especially 
in batch reactors; the output of these reactors are heterogeneous populations of 
crystals in both size and shape52. Multiple, energy intensive downstream 
operations are needed before tableting into the final product. Aside from increasing 
the complexity of the process, some of these steps such as comminution, milling, 
and granulation can result in amorphization and polymorphic transformation of the 
API crystals127–129. The blending of complex powder mixtures, containing 
processed API crystals, lubricants, fillers, binders, and other excipients, is 
inherently stochastic, and this process is complicated by separation and clustering 
of various components of the blend130,131. These challenges require a unique set 
of process parameters for every new formulation132. Processability, especially flow 
properties, of powder mixtures also heavily influence process parameters of 
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formulations133. 
 Emulsion-based crystallization directly addresses these issues. Kawashima 
first demonstrated the direct formation of spherical agglomerates of API crystal 
using this method54. These spherical agglomerates display better processability 
and dissolution properties, and the size distribution of the agglomerates is directly 
tied to the size distribution of the emulsions. Droplet microfluidics generate highly 
mono-disperse and tunable droplet populations134. The application of this 
technology to spherical crystallization approaches affords unprecedented levels of 
control of the crystallization process and product properties. The Khan lab has 
greatly expanded the capabilities of microfluidic emulsion-based crystallization to 
include simultaneous crystallization and formulation, resulting in the composite 
drug-polymer particles52,124,125,135. They have demonstrated composite particles 
composed of both hydrophobic and hydrophilic APIs and matrices. These methods 
provide high levels of structural control at the single particle level; high process-
based selectivity enables control of API polymeric form, and particle micro- and 
macro-structure can be control via matrix pore size and API distribution. This high 
level of structural control is thought to enable designer dosage forms with highly 
specialized release behavior66,136,137. Processability is increased compared to 
similar powder mixtures due to better flow properties and uniformity of each 
individual particle. These products are capable of being directly compacted into 
tablets, completely circumventing the high-energy, low efficiency steps of the 
traditional formulation process52. The combination of microfluidic-based 
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approaches with continuous, downstream extractive and evaporative 
crystallization methods intensifies and simplifies traditional manufacturing 
workflows enabling new paradigms in dosage form manufacturing138,139. 
 The increasing proportion of highly hydrophobic candidate APIs poses 
another strain on traditional formulation approaches44. Potentially effective 
moieties may be abandoned due to failures in formulation to provide sufficient 
solubility. API crystals prepared at the nanoscale show greatly improved solubility 
and dissolution properties. Biocompatible polymeric hydrogels have been 
demonstrated as a promising formulation and delivery vehicle for hydrophobic API 
nanocrystals140,141. The encapsulation of monodisperse nanoemulsion populations 
containing dissolved drug in the hydrogel is one approach to incorporating 
hydrophobic domains into the hydrophilic environment of the hydrogel65,66,142. The 
nanoemulsions act as individual crystallization reactors for the formation of 
nanocrystals. Crystallization occurs upon evaporation, and the hydrogel matrix 
isolates emulsions by counteracting evaporation-induced coalescence and 
confines the emulsions to limit the growth of crystals beyond the emulsion size. 
Both of these mechanisms control crystal size and morphology, and crystal size 
can be tuned by emulsion size and the concentration of API dissolved in the 
emulsion. This method has enabled the loading of fenofibrate crystals in alginate 
hydrogels at loading fractions of up to 85% by weight142. Composite hydrogel 
particles can provide tailored dosage and release properties65,143. 
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Structurally Controlled Release of Carbamazepine from Ethyl Cellulose Composite 
Microparticles 
Materials and Methods 
Materials. Poly(vinyl) alcohol (PVA) (M.W. 67,000), dichloromethane (DCM) 
(99.5%), ethyl cellulose (EC) (viscosity 10 cP), poly(lactic-co-glycolic acid) (PLGA) 
(50:50), and carbamazepine(CBZ) were purchased from Sigma-Aldrich 
(Singapore) and used as received. 5-Methyl-2-[(2-nitrophenyl)amino]-3-
thiophenecarbonitrile (ROY) was purchased from Nanjing Chemlin Chemical 
Industry Co. Ltd., China. Ultrapure water (18.3 MΩ) obtained using a Millipore Milli-
Q purification system was used to prepare aqueous PVA solution.  
 
Fabrication of Drug-Excipient Microparticle. A glass capillary microfluidic setup for 
emulsion generation was assembled with square and cylindrical glass capillaries 
(Arte Glass Associates, Japan) of ID 1.0 mm and 0.7 mm, respectively, as 
previously reported. The surface of the cylindrical glass capillary was plasma 
treated at 100 W for 120s. The treated cylindrical capillary was inserted co-axially 
into the square capillary. The dispersed phase consisted of solutions of both 
carbamazepine and ethyl cellulose dissolved in dichloromethane at a fixed mass 
ratio of 1 prepared at concentrations of 40 mg/mL and 60 mg/mL, used for the 
formation of janus and homogeneous particles, respectively. 3 wt % PVA in 
ultrapure water was used as the continuous phase. Continuous and dispersed 
phase solutions were infused from opposing ends of the square capillary by 
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syringe pumps (Harvard PHD 22/2000, Harvard Apparatus, Holliston, MA), where 
the two phases contact at the tapered tip of the cylindrical glass capillary in a flow-
focusing configuration, as shown in Figure 5.1. Flow rates for each phase were 
adjusted to obtain monodisperse droplets in the size range of 150−300 μm. 5.1 
and 5.7 cm I.D. glass wells were used for sample collection as well as solidification 
platforms. Glass wells were prefilled with a film of the continuous phase prior to 
the collection of 100 μL droplets. Excess continuous phase from droplet collection 
was removed after sample collection. Final film thickness was either 2.0 mm or 0.5 
mm for the formation of janus particles and homogenous particles, respectively. 
Evaporative solidification was done at 24 °C and 55% humidity. Particles were 
washed with ultrapure water and vacuum-dried for 5 h and 2 h for janus and 
homogeneous particles, respectively.  
 
Optical Microscopy. Optical microscopy images of the process and samples were 
captured using a Qimaging MicroPublisher 5.0 RTV camera (QImaging, Surrey, 
Canada) mounted on an Olympus SZX7 microscope (Olympus, Tokyo, Japan). A 
Leica CLS 150 XE light source was used for illumination (Leica, Wetzlet, 
Germany). 
 
Field Emission Scanning Electron Microscopy. A JEOL JSM-6700F field emission 
scanning electron microscope (FESEM) (JEOL, Peabody, MA) at 5 kV accelerating 
voltage was used to acquire further structural information on the microparticles. All 
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samples were prepared on conventional SEM stubs with carbon tape and were 
coated with ∼10 nm of platinum by sputter coating. To reveal the cross sections of 
the microparticles, regular scotch tape was used to adhere and remove parts of 
the microparticles. 
 
Digital Scanning Calorimetry. DSC thermograms were obtained using a Mettler 
Toledo DSC 882 apparatus (Mettler Toledo, Columbus, OH). Around 5 mg of 
sample was crimped in a sealed aluminum pan and heated at 3 °C/min in the range 
of 100−225 °C using an empty sealed pan as a reference. Dry nitrogen was used 
as purge gas with a flowrate of 50 mL/min. The instrument signal-to-noise ratio is 
∼12. 
 
Carbamazepine Standard Curve. CBZ was dissolved in ultrapure water at a 
concentration of 30.0 µg/mL. Dilutions were prepared from this solution at 1.0 
µg/mL, 5.0 µg/mL, 12.0 µg/mL, 18.0 µg/mL, 25.0 µg/mL. Absorbance of all 
solutions was measured at 285 nm on a Shimadzu UV-1800 Spectrophotometer 
(Shimadzu, Kyoto, Japan). Absorbance values were plotted as a function of 
concentration to prepare a standard curve. 
 
In Vitro Drug Release Testing. 6 mg of dry CBZ-EC microparticles were weighed 
and placed into a 250 mL glass jar filled with 100 mL of ultrapure water. The glass 
jar was sealed and placed on an orbital shaker set at 115 rpm. Samples of release 
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media, 0.5 mL with replacement, were taken over 120 hrs. Samples were taken 
between 0-2 hr at 20 min intervals, 2-4 hr at 30 min intervals, 4-10 hr at 1 hr 
intervals, and 10-120 hr at 12 hr intervals. Sampled media was measured at 285 
nm. Each particle type was tested in triplicate. Particles were recovered after 
release testing for FESEM analysis. 
 
Results 
Characterization of CBZ-EC microparticles. Figures 5.2A and 5.2B display 
brightfield optical microscopy images of homogeneous and janus particles, 
respectively. Homogeneous particles, prepared at 60 mg/mL CBZ/EC and 
solidified in 0.5 mm film, are characterized by a uniform consistency across their 
entire surface. Janus particles, prepared at 40 mg/mL CBZ/EC and solidified in 2.0 
mm film, have 2 distinct hemispheres. Drug and polymer are evenly distributed 
throughout the particle volume of homogeneous particles. CBZ is sequestered and 
distributed in EC in one hemisphere of janus particles; the other hemisphere is 
comprised of large pores, largely devoid of CBZ. Figure 5.3 displays finer details 
of particle cross-sections pre- and post-release testing. Pre-release, CBZ crystals 
are evenly distributed throughout an EC matrix in homogeneous particles, shown 
in Figure 5.3A. CBZ crystals are evenly distributed in an EC matrix in one 
hemisphere of janus particles while the other hemisphere, as shown in Figure 
5.3C. FESEM images of particles post release reveals that partitioning of drug in 
the janus particles resulted in a denser EC matrix in which drug was stored when 
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compared to the pore structure in the homogeneous particles, Figures 5.3D and 
Figures 5.3B, respectively. 
 Figure 5.4 shows DSC thermographs for homogeneous and janus particles. 
Both particle types show a single peak at 188 °C, indicating that CBZ is present 
only in polymorph form II. The broadening of the peak may be due to the presence 
of EC. 
 
Release from CBZ-EC particles. Figure 5.5 displays the standard curve of CBZ in 
water. Absorbance of CBZ increases linearly over a concentration range of 0-30 
µg/mL.  
 Figure 5.6A and 5.6B display the overall and short-term drug release 
profiles from both particle types, respectively. The release profiles of both particle 
types are of similar shape, but the janus particles release drug at a slower rate. 
Release profiles were fit to the Weibull function, previously defined in Chapter 4. 
Interestingly, the shape parameter, b, is approximately 0.5 for both particles, 
signifying diffusion-limited release, but the characteristic release tiem for the janus 
particles was twice that of the homogeneous particles.  
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Use of Ultrasonic Agitation Mediated Method to Study Release of Naproxen from 
Ethyl Cellulose Composite Microparticles 
Materials and Methods 
Materials. Naproxen (N8280), poly(vinyl) alcohol (PVA) (M.W. 67,000), and ethyl 
cellulose (viscosity 10 cP) were purchased from Sigma-Aldrich (St. Louis, MO).  
Ethyl acetate (HiPerSolv CHROMANORM® for HPLC, ≥ 99.8%) was purchased 
from VWR International, LLC (Franklin, MA). Ultrapure water (18.3 MΩ) was 
obtained from a Millipore MilliQ purification system. Polytetrafluoroethylene 
(PTFE) tubes of 0.02” and 0.04” I.D. were purchased from Cole Parmer, and 
Polyether Ethyl Ketone (PEEK) MicroTees (P-727, 0.020” thru hole, and P-890, 
0.006” thru hole) were purchased from IDEX Health & Science LLC. 
 
Formation of Drug-Excipient Microparticles. Naproxen (NAP) and ethyl cellulose 
(EC) solutions in ethyl acetate at different drug-polymer ratio were used as the 
dispersed phase; drug to polymer ratios of 2.5, 1.25, 0.75, 0.625, and neat 
naproxen. 3% w/w PVA in ultrapure water was used as the continuous phase. 
Harvard 22/2000 syringe pumps were used to pump both solutions to a PEEK 
MicroTee junction were droplets of dispersed phase in continuous phase were 
formed. Continuous and dispersed flow rates were 1000 µL/min and 30 µL/min, 
respectively, and resultant droplets were approximately 590 µm in diameter. The 
droplets flowed through a 30 cm, 0.4” ID PTFE tube (Cole Parner, Vernon Hills, IL) 
into the bottom of a 50 cm tall collection tower containing an excess of ultrapure 
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water (> 1L). The lower density of the dispersed phase relative to the continuous 
phase caused the droplets to rise. Ethyl Acetate is extracted by the aqueous media 
causing the particles to start to solidify. Fully solidified particles then reverse 
course and sink to the bottom. Figure 5.7 shows a schematic of this process. 
 
Optical Microscopy. Optical microscopy images of dried particles were captured 
using a Qimaging MicroPublisher 5.0 RTV camera mounted on an Olympus SZX7 
microscope, with illumination using a Leica CLS 150 XE light source. 
 
Field Emission Scanning Electron Microscopy. A JEOL JSM-6700F field-emission 
scanning electron microscope at 5 kV accelerating voltage was used to image the 
microparticles. All samples were prepared on conventional SEM stubs with carbon 
tape and were coated with ~10 nm of platinum by sputter coating. To reveal the 
microparticle cross sections, a 21G needle was used to manually shear the 
microparticles under an optical microscope prior to SEM observation. 
 
Powder X-Ray Diffraction. Polymorphic characterization of the neat naproxen and 
naproxen-ethyl cellulose composite microparticles were analyzed using powder X-
ray diffraction (PXRD) to examine their crystallinity. An Bruker D8 Advance X-ray 
diffractometer (Bruker, Billerica, MA) was operated at 40 kV, 30 mA and a scanning 
rate of 1.06 °/min over a range of 2θ from 2.5−30° using a Cu radiation wavelength 
of 1.54 Å. 
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Digital Scanning Calorimetry. DSC thermograms were obtained using a Mettler 
Toledo DSC 882 apparatus (Mettler Toledo, Columbus, OH). Around 5 mg of 
sample was crimped in a sealed aluminum pan and heated at 3 °C/min in the range 
of 100−225 °C using an empty sealed pan as a reference. Dry nitrogen was used 
as purge gas with a flowrate of 50 mL/min. The instrument signal-to-noise ratio is 
∼12. 
 
Naproxen Standard Curve. NAP was dissolved in ultrapure water at a 
concentration of 100 µg/mL. Dilutions were prepared from this solution at 10.0 
µg/mL, 25.0 µg/mL, 0 µg/mL, 50.0 µgmL, 75.0 µg/mL. A modular 
spectrophotometer (FLAME-T, Ocean Optics, Largo, FL, USA) connected to a UV-
light source (DH-2000-BAL, Ocean Optics) measured absorbance of the sample 
solutions at 270 nm. OceanView software was used to record and export 
absorbance data for analysis. 
 
Adopting Ultrasonic Agitation Release Method for Use with Microparticle Samples. 
The ultrasonic mediated release test was set up as described in Chapter 3. The 
test media used was 1x PBS. NAP-EC particles prepared at 50 mg/mL NAP and 
40 mg/mL EC were added to the vessel such that the total mass of drug was 
approximately 1.4 mg. Particles were fully wetted with a small aliquot of test media 
and transferred to the test using a P1000 pipette. Drug release tests were 
performed at an amplitude setting of 30% and 45%. The absorbance of sampled 
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media at 270 nm was measured using a Spectramax M5 spectrophotometer. 
 
Ultrasonic Agitation Mediated Release Testing of NAP-EC Composite Particles.   
A Phosphate-Buffered Saline (PBS) stock solution was prepared by dissolving a 
5g Gibco PBS tablet into 500 mL of ultrapure water., and the test media used for 
all samples was 50 mL of the PBS solution. The mass of each particle type used 
per test was set such that the expected amount of naproxen was approximately 
2.5 mg. A 60 mL round-bottom, plastic test tube (BRAND®, Sigma-Aldrich, St. 
Louis, MO, USA) was used as the test vessel. To start the release test, particle 
samples were pre-wetted with a 400 µL aliquot of test media and transferred to the 
test vessel using a micropipette. A 40 kHz ultrasonic generator with a 0.125 in 
diameter microprobe horn (Vibracell VCX134FSJ; Sonics, Newtown, CT, USA) 
was used to apply ultrasonic agitation to the test media for 7200 sec after the 
particles were added at an amplitude setting of 45% and a probe height of 55 mm. 
A continuous, closed-loop sampling system was set up to monitor the amount of 
drug release over time – a peristaltic pump (BT50S/YZ15, Lead Fluid, Baoding, 
Heibei, China) transported dissolved drug solution from the test vessel through a 
1 µm pore size cannula filter (QLA, Telford, PA, USA) and 0.2 µm in-line syringe 
filter (0.25 mm diameter, FLL/MLS CA; GVS Life Sciences, Sanford, Maine, USA) 
to a flow cell (20 mm path length, SMA-Z-20-PEEK, FIA Labs, Seattle, WA, USA) 
and back into the test vessel. A modular spectrophotometer (FLAME-T, Ocean 
Optics, Largo, FL, USA) connected to a UV-light source (DH-2000-BAL, Ocean 
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Optics) measured absorbance of the sampled solution at 270 nm. OceanView 
software (Ocean Optics) was used to record and export absorbance data for 
analysis. At the end of each test, the system was cleaned by passing 10 mL of test 
media through the sampling system. Each sample was tested in triplicate. 
Appendix B contains an SOP document for setting up this sampling system. 
 
Results 
Characterization of NAP-EC microparticles. Particles prepared at all drug loading 
fractions were monodisperse and spherical with average diameters 160-170 µm.  
FESEM image analysis revealed that all naproxen-ethyl cellulose microparticles 
had a distinct thin and smooth surface coating of ethyl cellulose. The structures for 
microparticles with drug-polymer ratios of 2.5 and 1.25 were found to be similar, 
and the structure of the latter is shown in Figure 5.8A-5.8C. The pores at the 
particle surface were slightly larger than in the center. Naproxen-ethyl cellulose 
microparticles with a drug polymer ratio of 1.25 had some faceted naproxen 
crystals embedded in the smooth ethyl cellulose pores. Conversely, microparticles 
with a drug-polymer ratio of 0.625 and 0.75 were composed of a dense matrix of 
amorphous smooth polymer and faceted needle-like drug crystals in the particle 
center; Figure 5.8D-5.8F displays FESEM images of particles with a drug-polymer 
ratio of 0.75. The formation of a core-shell structure with a thin porous polymer 
shell at the particle surface may be attributed to the high water content at the 
droplet boundary which facilitates the phase inversion of ethyl cellulose polymer 
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from a liquid to a solid phase at the immediate interface of the droplet. 
 Figure 5.9 displays powder x-ray diffraction spectra of particle samples. The 
spectra of all samples, including neat NAP microparticles, closely resembles the 
confirmed spectra for polymorphic form I. DSC thermographs, displayed in Figure 
5.10, are inconclusive in terms of polymorph present. The peaks of the 3 composite 
particles tested are all broadened and shifted towards lower temperatures, 
possibly due to the presence of EC. 
 
Release from NAP-EC Particles. Figure 5.11 displays the absorbance of solutions 
of various concentrations of NAP in 1X PBS. Absorbance increases linearly from 
concentrations of NAP from 0.0 mg/mL to 0.1 mg/mL.  
 Preliminary ultrasonic agitation mediated release experiments with 
microparticle samples were performed to determine appropriate system 
parameters for testing. Based off of results and observations from characterization 
experiments in Chapter 2, probe height was fixed at 55 mm to allow for circulation 
of test media throughout the entire vessel. Figure 5.12 displays release testing 
results performed at 30% and 45% amplitude setting. The higher amplitude setting 
resulted in faster release behavior. An amplitude setting of 30% resulted in a 
similar amount released compared to the 45% amplitude setting case, in contrast 
to the observations from the experiments described in Chapter 3. In the case of 
the microparticles, an amplitude setting of 30% resulted in a high enough bulk flow 
to keep most particles suspended over the duration of the test. Particles were still 
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present in solution after 2 hours of ultrasonic agitation in both cases. 
 Figure 5.13 displays a release profiles of neat naproxen and naproxen-ethyl 
cellulose microparticles of drug-polymer ratios 2.5, 1.25, 0.75 and 0.625. The wide 
range and variety of dissolution profiles obtained crucially highlights the 
applicability of the method to easily formulate functional microparticles by tuning 
particle composition. Neat naproxen showed the fastest rate of release with 80% 
of drug released by ~300s. The presence of ethyl-cellulose generally led to delayed 
drug release from the naproxen-ethyl cellulose particles, and an inverse 
relationship between the drug-polymer ratio and the overall rate of drug release 
was observed; for drug polymer ratios greater than 1, complete drug release was 
reached by the end of the test at 7200 sec, with 80% drug release observed at 
~900s and ~2250s for microparticles with a drug-polymer ratio of 2.5 and 1.25 
respectively. In contrast, for drug-polymer ratios below 1, only ~40% of the drug 
was released at the end of the dissolution test. 
 Post-release FESEM images of naproxen-ethyl cellulose particles with 
drug-polymer ratio of 1.25 and 0.75 are displayed in Figure 5.14A and 5.14C, 
respectively. Spent NAP-EC microparticles with a drug-polymer ratio greater than 
1 have pores present their center, as shown in Figure 5.14B. NAP-EC particles 
with a drug-polymer ratio of 0.75 had areas of observable smooth patches of 
polymer with no visible pores, as shown in Figure 5.14D. 
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Release from Composite Hydrogel Particles and Comparison to USP Method 
Materials and Methods 
Materials. Fenofibrate (>99 % pure), anisole, >99% pure), sodium dodecyl sulfate 
(>99% pure), Span 80, Tween 80, and sodium alginate were purchased from 
Sigma-Aldrich (St. Louis, MO).  
 
Formation of fenofibrate loaded alginate particles. Fenofibrate nanoemulsions and 
alginate hydrogels loaded with fenofibrate nanocrystals were prepared as 
described in Badruddoza et al.143. Briefly, fenofibrate dissolved at 400.0 mg/mL in 
anisole was used as the dispersed phase. 2% w/v sodium alginate in DI water was 
used as the continuous phase. Nanoemulsions were prepared by adding dispersed 
phase to a mixture of continuous phase, Tween 80, and Span 80 using a magnetic 
stirrer for 10 min at 1000 rpm and 25 °C. Average nanoemulsion size is determined 
by DLS. The nanoemulsion mixture was then added dropwise, either by gravity or 
centrifugal force, through a needle into a 6% w/v calcium chloride bath; cross-
linking of the alginate hydrogel occurs immediately upon contact with the bath. 
Particles were removed, rinsed with water, and dried at 60 °C for -4 days. 
Nanocrystals form due to evaporation and the overall particle diameter shrinks 
during the drying step. Droplet size, and final particle size, are controlled by the 
gauge of the needle. Final particle diameters are determined by optical 
microscopy. 5 particles with different diameter were prepared; particle and 
nanocrystal diameter are displayed in Table 5.2.  
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Dissolution Testing Using USP Apparatus II. Release testing of all 5 FEN-loaded 
alginate particle samples were performed in USP apparatus II. ~ 40 mg of particles 
were added to 900 mL 0.72% w/v SDS and the paddle was operated at 75 rpm for 
each test. Tests were performed at either 25 °C or 37 °C – Table 5.1 also displays 
test conditions for each tablet type. Dissolution tests were performed for 24 hrs to 
ensure complete release of drug. Absorbance of the solution was measured at 285 
nm throughout the test duration using a Varian UV-Vis Cary 50 spectrophotometer 
(Varian, Palo Alto) and in situ dip probe. As a control, DT-048 particles (d = 250 
µm) were crushed using a mortar and pestle to de-aggregate and lower the mean 
particle diameter, and dissolution testing was performed on this modified sample. 
All particle samples were tested in triplicate. 
 
Drug Release Testing Using Ultrasonic Agitation Mediated Method. The ultrasonic 
mediated release test was set up as described in Chapter 3. The test media used 
was 0.72% w/v SDS. FEN loaded alginate particles were added to the vessel such 
that the total mass of drug was approximately 1.0 mg by directly dumping weighed 
out samples into the test media. The initial temperature of the release media was 
22 oC in all cases. Drug release tests were performed at a probe height of 55 mm 
and an amplitude setting of 45%. Media was sampled continuously by the closed-
loop system, and the absorbance of sampled media at 285 nm was measured 
using a Spectramax M5 spectrophotometer every 5 sec. As a control, DT-048 
particles (d = 250 µm) were crushed using a mortar and pestle to de-aggregate 
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and lower the mean particle diameter, and drug release testing was performed on 
this modified sample. All particle samples were tested in triplicate. 
 
Results 
Dissolution Testing Using USP Apparatus II. Previous work performed by the 
Doyle lab have shown that release rates of FEN from alginate hydrogels can be 
tuned by particle diameter, crystal size, and drug loading fraction – API release 
rates decrease with increasing values of each parameter143. Crystal size was held 
constant in the studies reported here.  
Figure 5.15 displays dissolution profiles of FEN from unmodified and 
crushed DT-048 particles at 25 °C. The time until 80% of drug is released from 
crushed DT-048 particles is lower than from unmodified particles.  
Dissolution profiles generated from samples DT-048, DT-104A, and DT-
104B at 37 °C are displayed in Figure 5.16. The time until 80% release was lower 
for DT-048 samples compared to both DT-104A and DT-104B particles. There was 
no observable difference in time until 80% released from DT-104A and DT-104B 
samples.  
Dissolution profiles generated from samples DT-048, DT-115A, and DT-
115B at 25 oC are displayed in Figure 5.17. The time until 80% release was lower 
for DT-048 samples compared to both DT-104A and DT-104B particles. There was 
no observable difference in time until 80% released from DT-104A and DT-104B 
samples.  
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Drug Release Testing Using Ultrasonic Agitation Mediated Method. Drug release 
profiles generated from unmodified and crushed DT-048 particles are displayed in 
Figure 5.18. The time until 80% release from crushed particles is lower than from 
unmodified particles.  
 Average drug release profiles from all particle samples are displayed in 
Figure 5.19. There is no clear trend between particle radius and time until 80% 
release. Interestingly, time until 80% release for DT-115A and DT-115B particles 
are very similar, but the initial rate of release from DT-115A particles is faster. 
Table 5.3 displays the time until 50% released (t50%) and time until 80% released 
(t80%) for all particle tested at 22 °C on the ultrasound system and 25 °C on the 
USP system as the average ± standard deviation. 
 
Discussion 
 The polymeric and hydrogel microparticles, and their associated fabrication 
processes, discussed in this chapter represent new approaches to formulation and 
dosage form development that provide numerous advantages in the simplification 
and intensification over traditional methods. The fine structural control at the 
individual particle level can enable the production of “designer” dosage forms with 
tailored release behavior. To fully achieve this goal, knowledge of both how dosage 
form structure affects release behavior and how dosage form structure can be 
tuned by manufacturing process parameters is needed. High-throughput and low 
cost drug release testing methods would facilitate these studies. The dosage forms 
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and fabrication processes discussed here are still in the experimental investigation 
phases, and, as such, particle production throughput is quite low compared to 
industrial, batch-scale processes. This low-throughput makes iterative release 
testing of sample dosage forms time-consuming and expensive. USP testing of the 
FEN-loaded alginate particles described in this chapter required approximately 15-
20 mg of API per test. The low volume nature of the ultrasonic agitation mediated 
method required only 1 mg of API per test. This 15-20x decrease in amount of 
sample need per test greatly improves the ability of the pharmaceutical scientist to 
iterate through both formulations and processes.  
 The droplet microfluidic–based approaches have been shown to result in 
highly uniform fabrication of drug-loaded polymeric particles with a large variety of 
highly complex internal structures. Process parameters such as drug loading 
fraction, drug-polymer ratio, and rates of solvent evaporation and extraction result 
in a complex design space with fine control of particle micro- and macro-structure, 
as well as the molecular and polymeric form of API and excipients. Release studies 
performed with CBZ-EC and NAP-EC particles clearly demonstrate that these 
structural differences affect drug release properties. In the case of the CBZ-EC 
studies, drug-loading fraction and rate of solvent evaporation result in 2 distinct 
particle macrostructures – homogeneous vs janus – which were demonstrated to 
have different drug release behaviors. The Weibull model was chosen as a 
generalized, empirical model for model-dependent parameter comparison. Both 
particle types had a fitted scale parameter of ~ 0.5 indicating that release is 
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diffusion limited and occurs through a fractal substrate. Post-release FESEM 
analysis revealed that the average pore size in the drug carrying hemisphere of 
the janus particles was smaller than the average pore size throughout the 
homogeneous particles (Figure 5.3). This observation at least partially explains the 
increased characteristic release time from the janus particles because the smaller 
pore sizes would result in higher diffusional resistances.  
 Macrostructural changes were also shown to affect release behavior from 
NAP-EC particles prepared at drug-polymer ratios ranging from 0.67-2.5. All 
particles displayed a “core-shell” structure with a thin shell of porous EC at the 
surface of the particles. FESEM images of particles post-release suggest that the 
observed differences in release behavior are due to differences in pore structure. 
Particles with drug-polymer ratios less than 1 showed areas of amorphous EC with 
no pores. The less porous interior of these particles could contribute to the retarded 
drug delivery ability in these particles compared with the more porous interiors of 
particles prepared at drug-polymer ratios greater than 1. Further analysis is 
needed to determine whether differences in release rates from particles with drug-
polymer ratios of 2.5 and 1.25 are due differences in shell thickness, matrix 
density, or other factors. 
 Release testing of hydrogel samples using the ultrasonic agitation based 
method was not able to fully reproduce general trends between particle diameter 
and release observed when release testing was performed in USP apparatus. One 
possible explanation for this discrepancy is that ultrasonic agitation may lead to 
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faster and functionally different breakdown of the alginate matrix. Although the 
alginate matrix was observed to fully dissolve at the end of all tests regardless of 
agitation method, ultrasonic agitation may result in mechanistically different 
breakdown of the matrix compared to mechanical agitation. Identifying the root 
cause of this difference is the focus of on-going work. These results highlight an 
important fact that the method described in this dissertation may not be applicable 
to all dosage forms. 
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Figure 5.1. Experimental Setup for the Production of Drug and Excipient Co-
Formulated Microparticles. 
Drug and excipient (e.g. carbamazepine and ethyl cellulose) are dissolved at 
various concentrations in DCM and used as the dispersed phase. An aqueous 
surfactant solution is used as the continuous phase. Each phase is introduced in 
a concentric glass capillary microfluidic device in a counter-flow configuration. 
Continuous phase films of various thickness are used to collect droplets. Taken 
from Yeap, …, Acevedo, et al. 2017. 
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Figure 5.2. Brightfield Images of Homogeneous and Janus CBZ-EC Particles. 
(A) Homogeneous particles. (B) Janus particles. Taken from Yeap, …, Acevedo, 
et al. 2017. 
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Figure 5.4. FESEM Images of CBZ-EC Particles Pre- and Post-Release. 
FESEM images of cross sections of homogeneous CBZ-EC particles, (a) pre-
release and (b) post-release. Images showing capturing the differences in porosity 
in the two halves of the janus particles (c) pre-release and in the (d) sub-micron 
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pore region and (e) microscale pore scale region post-release. Taken from Yeap, 
…, Acevedo, et al. 2017. 
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Figure 5.4. DSC Thermogram of CBZ-EC Particles. 
DSC thermograms of janus and homogeneous CBZ-EC particles. 
  
128 
 
 
 
Figure 5.5. Standard Curve of CBZ. 
Absorbance vs concentration of CBZ dissolved in water. 
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Figure 5.6. Drug Release from CBZ-EC Particles. 
(A) Drug release profiles from janus and homogeneous CBZ-EC particles. The 
dotted inset marks the short-term drug release, magnified in (B). The Weibull 
model was fitted to the data, where m(t) is the normalized fraction of CBZ released 
with time, Td is a characteristic time for 63.2% drug to be released, and b is the 
shape parameter. Taken from Yeap,…, Acevedo et al. 2017.  
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Figure 5.7. Schematic of Extractive Crystallization Method for NAP-EC 
Particle Formation. 
Drug or drug-excipient droplets formed at T-junction undergo extractive 
crystallization in water-filled reactor. Solidified particles sink to bottom of reactor 
for easy collection. Taken from Yeap, Acevedo et al. submitted. 
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Figure 5.8. FESEM Images of NAP-EC Particles. 
FESEM images of naproxen-ethyl cellulose microparticles with drug-polymer ratio 
of 1.25 and 0.75 shown in (a) – (c) and (d) – (f) respectively. The overall particle 
morphology is shown in the first row, with the cross section featured in the second 
row, and a zoom in of the cross section (marked out in the white box) is shown in 
the last row. Taken from Yeap, Acevedo et al. submitted.  
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Figure 5.9. X-ray Powder Diffraction Spectra of NAP-EC Particles. 
Powdered X-Ray Diffraction spectra of (a) naproxen-ethyl cellulose microparticles 
with drug-polymer ratio of (a) 0.625, (b) 0.75, and (c) 2.5. The spectrum of neat 
naproxen microparticles is shown in (d), and the reference spectrum of Form I 
reported by Song and Sohn is adapted and shown in (e). Taken from Yeap, 
Acevedo et al. submitted. 
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Figure 5.10. DSC Thermogram of NAP-EC Particles at Various Drug-Loading 
Fractions. 
DSC thermograms for NAP-EC and NAP neat particles. Melting peaks of all NAP-
EC are shifted left relative to NAP neat particles. 
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Figure 5.11. Naproxen Standard Curve. 
Absorbance of NAP solutions at 270 nm. 
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Figure 5.12. Determination of Test Parameters for Microparticle Samples. 
NAP-EC 50-40 particles dissolved at amplitude settings of 45% and 30%. 3 tests 
were performed at each amplitude setting. 
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Figure 5.13. Release from NAP-EC Particles. 
Drug release profiles from neat NAP and NAP-EC particles of different drug-
polymer ratios. Taken from Yeap, Acevedo et al. submitted. 
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Figure 5.14. Post-Release FESEM Images of NAP-EC Particles. 
Cross sections of NAP-EC particles post-release. (a) Drug-polymer ratio of 1.25, 
(c) drug-polymer ratio of 0.75. (b) and (d) represent the ROIs displayed in (a) and 
(c), respectively. Taken from Yeap, Acevedo et al. submitted. 
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Sample ID Diameter (µm) Test Conditions 
DT-048 250 
USP (25 °C, 37 °C) 
Ultrasound (22 °C) 
DT-104A 495 
USP (37 °C) 
Ultrasound (22 °C) 
DT-104B 380 
USP (37 °C) 
Ultrasound (22 °C) 
DT-115A 734 
USP (25 °C) 
Ultrasound (22 °C) 
DT-115B 1090 
USP (25 °C) 
Ultrasound (22 °C) 
 
Table 5.1. Overview of FEN-Alginate Particles. 
Sample ID, diameter, and testing conditions of FEN-alginate microparticles. 
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Figure 5.15. USP Release from Crushed FEN-Alginate Particles. 
Drug release profiles from unmodified DT048 (black) and crushed DT048 (red) 
particles at 25 °C. All samples were tested in triplicate. 
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Figure 5.16. USP Release from FEN-Alg Particles at 37 °C. 
Release profiles of DT048, Dt104A, and DT104B particles in USP II at 37 °C. All 
samples were tested in triplicate.  
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Figure 5.17. USP Release from FEN-Alg Particles at 25 °C. 
Release profiles of DT048, DT115A, and DT1015B particles in USP II at 25 °C. All 
samples were tested in triplicate. 
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Figure 5.19. Ultrasound Release from Crushed FEN-Alginate Particles. 
Drug release profiles from unmodified DT048 (black) and crushed DT048 (red) 
particles at 22 °C using ultrasonic agitation mediated test. All samples were tested 
in triplicate. 
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Figure 5.19. Average Release Profiles Generated Using Ultrasonic Agitation 
Method. 
Average release profiles of DT048, DT104A, DT104B, DT115A, and DT1015B 
particles in ultrasound system at 22 °-C. All curves represent average of 3 runs. 
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Sample ID Ultrasound (22 °C) USP (25 °C) 
 t50% t80% t50% t80% 
DT048 (250 µm) 9.14 ± 
0.21 
21.56 ± 
0.13 
40.5 ± 
5.29 
98.67 ± 
10.61 
DT104B (380 µm) 9.22 ± 
0.79 
21.44 ± 
2.66 
--- --- 
DT104A (495 µm) 7.06 ± 
1.06 
16.11 ± 
1.06 
--- -- 
DT115A (793 µm) 13.81 ± 
0.24 
2 ± 2.09 69.33 ± 
0.29 
162.17 ± 
11.55 
DT115B (1090 µm) 16.42 ± 
0.47 
27.75 ± 
0.82 
63.14 ± 
4.04 
153.83 ± 
2.89 
 
Table 5.2. Comparison of Time to 50% and 80% Release Between Methods. 
The time until 50% release and 80% release of each particle type achieved by 
both the ultrasound method and USP II. DT104A and B not tested at 25 oC. Data 
displayed as average ± standard deviation, n =3. 
  
145 
 
 
CHAPTER 6: POST MARKET SURVEILLANCE AND MEDICINE QUALITY 
SCREENING 
 
Globally, poor quality medicines comprise an estimated $75 billion of a $962 
billion market144. They are responsible for over 100,000 preventable deaths and 
many more failed treatments annually, and in the case of substandard medicines, 
the spread of drug resistant pathogens145. Substandard medicines – medicines 
that display sub-optimal bioavailability due to improper manufacturing or storage – 
have recently been recognized as a significant part of the problem, especially in 
the developing world. Being able to detect substandard medicines in the field, 
close to the point-of-care, is of major importance. Current laboratory methods are 
reliable, but they are costly, time intensive, and complex, reducing their overall 
effectiveness in low and middle-income countries. Numerous field-based 
technologies that screen for the presence of active pharmaceutical ingredient (API) 
or packaging validity have been developed; however, these markers are not 
suitable for substandard medicine screening. Quantitative assessment of API 
content as well as analysis of API kinetic release profiles provide crucial 
information on medicine quality. Dissolution testing is the gold standard in 
performing the latter analysis. There are currently no field-oriented technologies 
capable of performing either type of test. 
The Zaman lab has developed PharmaChk – a portable platform for fully 
automated API quantification and drug release testing – to fill this gap. This chapter 
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describes the incorporation of the ultrasonic agitation system into the PharmaChk 
instrument for automated sample preparation, and the use of the instrument in the 
end-point analysis of API content from multiple tablet types. Outcomes and 
feedback from a field trial and demonstration performed in collaborations with the 
Center for Pharmaceutical Advancement and Training (CePAT) in Accra, Ghana 
are discussed. The chapter ends with a discussion on technical considerations of 
performing drug release testing on the PharmaChk instrument and data analysis 
approaches. 
 
Background 
Counterfeit, Falsified, and Substandard Medicines 
 Pharmaceutical products are ubiquitous in the fight against treating disease. 
Globally, pharmaceutical sales are on track to break $1 trillion by 2020146. The 
World Health Organization estimates that up to 10% of pharmaceuticals available 
around the globe are of sub-par quality. Despite the tight regulatory environment 
in the United States, about 1% of medicines are considered counterfeit or falsified, 
the majority of which are lifestyle drugs that enter the US through sales from over-
seas, online-only “pharmacies.” The problem of poor-quality medicines 
disproportionally affects low-resource and developing areas due to loosely 
controlled regulatory standards in the procurement, manufacturing, and 
distribution of medicines. These medicines are estimated to result in the loss of 
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100,000 lives annually and many more failed treatments147. Studies on medicine 
quality have shown that upwards of 20-30% of all medicines in countries in sub-
Saharan Africa, Southeast Asia, and Latin America are poor quality145,148–151. This 
issue becomes extremely troubling when viewed through the lens of deadly, but 
treatable, diseases such as malaria, tuberculosis, and HIV/AIDS. The prevalence 
of poor-quality medicines compounds the already heavy health and economic 
burdens of these diseases.   
Poor quality medicines are classified as either counterfeit or substandard. 
Counterfeit medicines refer to medicines that were knowingly falsified by the 
manufacture148. These medicines often do not contain the stated API and are 
packaged incorrectly. Substandard medicines display sub-optimal bioavailability 
due to errors in the manufacturing process, the use of incorrect ingredients, or poor 
transportation or storage conditions148. Aside from failed treatments, substandard 
medicines have also been linked to increases in rates of development of drug 
resistance by pathogens152,153. These types of medicines are increasingly being 
recognized as a significant part of the problem – in a 2006 study, 68% of 
antimalarial medicines collected in Laos, Burma, Vietnam, and Cambodia did not 
contain the correct of amount of active ingredient151. 
Counterfeit and substandard medicines are a very complex global health 
issue, and the scope of the problem is not very well understood; both types of 
medicines can exist at any point along the supply chain making detection and 
preventative measures difficult to achieve145. USP defines 4 metrics by which they 
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assess a products quality – 1) identification of presence of API, 2) identification of 
presence of impurities, 3) quantification of API content, and 4) analysis of 
dissolution. Counterfeit and substandard medicines perform differently across 
these metrics making any one approach ill-suited for the screening of both types. 
Attempts to assess the issue have resulted in the development of technologies to 
detect counterfeit medicines in the field. These technologies have used 
chromatography, chemistry, and optical methods to identify the presence of API 
and impurities and the validity of packaging149,153–158. The Global Pharma Health 
Fund MiniLab® is the main technology used in the field to analyze medicine quality. 
This test uses thin layer chromatography to provide a semi-quantitative measure 
of API content. However, no field-based tests provide sufficient information to 
screen for substandard medicines158. A quantitative assessment of API content 
and a metric for drug release behavior are required to screen for substandard 
medicines. There are currently no field-ready technologies able to perform either 
type of this analysis.    
 
PharmaChk 
 PharmaChk is a portable and fully automated instrument for the assessment 
of API content and drug release behavior of tablets159. The instrument is composed 
of four major components including a tablet dissolving apparatus, fluidic handling 
system, a microfluidic module, and optical detection system. The microfluidic 
module mixes incoming solutions of dissolved tablet and a light-emitting probe, 
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specific to the drug molecule of interest, to release a light signature. This light is 
then captured as an image and compared against the light emitted from a co-run 
reference solution of known API concentration to calculate API content of the 
sample. Figure 6.1 diagrams this process.  
 Tablets are dissolved in 50 mL of media via an ultrasonic horn; stirring-
based approaches to tablet dissolution using paddles and magnetic stir-bars were 
found to be cumbersome at volumes of 50 mL and raised concerns of cross 
contamination due to high degrees of submersion of the agitation elements in the 
test media. Sonics and Materials (Newton, CT) were found to offer 50 W and 100 
W ultrasound generators. The 50 W generator was chosen as it meets input power 
needs and minimizes the physical footprint of the system. The generator is used 
to power a 3.18 mm diameter horn. The horn was set at a fixed probe height of 35 
mm. A fluidic handling system withdraw and filter media from the test media and 
perform dilution of the sampled media if necessary. The fluidic handling system 
then pumps the sampled media into the microfluidic module for analysis. The test 
media can be sampled once the tablet is fully dissolved for end-point quantification 
of API or at multiple time-points while the tablet is dissolving to generate a drug 
release curve. 
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Development of End-Point Testing Protocols for Amodiaquine Tablets 
Materials and Methods 
Materials. Amodiaquine hydrochloride (AQ) and Eosin Y were purchased from 
Sigma Aldrich (St. Louis, MO). Camosunate tablets containing 300 mg AQ (Batch: 
1507232) and Winthrop tablets containing 270 mg AQ (Batch: 5MA304) were 
sourced from Accra, Ghana. Ultrapure water was obtained from Milli-Q filtration 
system. 
 
Amodiaquine Standard Curve.  AQ was dissolved in ultrapure water at a 
concentration of 5.4 mg/mL. This amodiaquine solution was diluted in 2 steps to a 
final concentration of 0.027 mg/mL – the solution was first diluted to 0.54 mg/mL 
by adding 1 mL of AQ solution to 9 mL of ultrapure water, then adding 0.5 mL of 
the diluted solution to 9.5 mL of ultrapure water. AQ solutions of concentration 
0.000 mg/mL, 0.007 mg/mL, 0.014 mg/mL, 0.020 mg/mL were prepared from the 
0.027 mg/mL AQ solution.  3 aliquots of 100 µL of each AQ solution were added 
to wells of a clear-bottom, black 96-well plate (Corning, Corning, NY). Eosin-Y 
probe solution, prepared at a concentration of 0.1 mg/mL in ultrapure water, was 
added to each well at a volume 100 µL. Fluorescence was measured using a 
SpectraMax M5 plate reader (Molecular Devices, San Jose, CA) at the following 
settings, 485nm/535nm excitation/emission, 50 flashes/read, bottom-read. 
Fluorescence values were plotted as a function of sample concentration, and a 
linear relationship was determined. 
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Stability of Amodiaquine in Presence of Ultrasound. Solutions of 0.027 mg/mL AQ 
in ultrapure water and 0.1 mg/mL Eosin-Y in ultrapure water were prepared as 
described above. The AQ solution was added to a 65 mL glass test tube 
(Chemglass, Vineland, NJ). The ultrasonic horn was inserted in the test tube at a 
probe height of 50 mm.  Sonication was applied at 50% amplitude setting for 10 
minutes. The AQ solution was sampled at 1 min, 3 min, 5 min, 8 min and 10 min. 
Samples were taken using a P1000 pipette. 3 100 µL aliquots of each sample were 
added to a 96-well microplate. 100 µL of Eosin-Y solution was added to each 
sample aliquot, and fluorescence was measured as described above. The 
concentration of amodiaquine in each sample was calculated using a standard 
curve as prepared and determined above. 
 
Consistency of Automated Dilution Protocol. A 2.7 mg/mL AQ solution in ultrapure 
water was prepared. The PharmaChk instrument was used to dilute the solution 
by a factor of approximately 200. A 500 µL aliquot of the diluted sample taken 
using a P1000 pipette was set aside for analysis. The PharmaChk instrument was 
cleaned with ultrapure water. This process was repeated for a total of 5 times using 
the same batch solution of 2.7 mg/mL AQ as the solution to be diluted. Diluted 
samples were analyzed using the Eosin-assay on the plate reader as described 
above. 
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Determination of Time Required to Dissolve Camosunate and Winthrop Tablets. 
Camosunate and Winthrop tablets were dissolved by the ultrasonic horn by the 
PharmaChk instrument in 50 mL ultrapure water. Probe height and amplitude 
setting were set to 35 mm and 50%, respectively. Ultrasonic agitation was applied 
for 10 min total. Every 2 min, the horn was turned off and removed so the media 
could be sampled. 600 µL of test media were removed by P1000 pipette and 
filtered through a 0.2 µm pore size syringe filter. Samples were diluted by a factor 
of 200 and analyzed on the plate reader as described above. 3 tablets of each type 
were tested. 
 
Quantification of Amodiaquine from Tablets Dissolved by Mechanical and 
Ultrasonic Agitation. Camosunate and Winthrop tablets were prepared in 3 
different ways. In the first method, tablets were crushed using a mortar and pestle, 
and the crushed tablet powder was added to 50 mL ultrapure water. The mixture 
was placed on an orbital shaker for 30 min. After 30 min, the dissolved tablet 
solution was sampled and filtered through a 0.2 µm pore size syringe filter. In the 
second method, tablet samples were prepared in the same way, except dissolved 
tablet solutions were filtered through a 10 µm pore size cannula filter. In the third 
method, tablets were dissolved by ultrasonic agitation for 6 min at a probe height 
of 35 mm and an amplitude setting of 50%. The dissolved tablet solution was 
sampled at 6 min and filtered through a 0.2 µm syringe filter. All samples of 
dissolved tablet solutions were diluted by a factor of 200 in ultrapure water. Diluted 
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samples were analyzed using the plate reader as described above. 3 tablets were 
tested for each approach. 
 
Repeatability of AQ Quantification from PharmaChk Instrument. The PharmaChk 
instrument was used to quantify amount of AQ from Camosunate and Winthrop 
tablets. 41 Camosunate AQ tablets were tested, and 38 Winthrop tablets were 
tested. Testing setup was prompted by companion software, and all test steps 
were automated. Briefly, tablets were dissolved in 50 mL ultrapure water. 
Ultrasonic agitation was applied for 6 min at 35 mm probe height and 50% 
amplitude setting. Media was sampled at 6 min and filtered through 10 µm pore 
size cannula filter. Sampled media was diluted and flowed through microfluidic 
module where it was mixed with Eosin-Y probe solution. AQ reference solutions of 
known concentration were also mixed with probe in the microfluidic module. AQ 
and probe solutions were excited by LED, and emitted light was captured via CCD 
camera. AQ concentration of sample solution was calculated by comparison of 
fluorescence to that of reference solutions. 
 
Results 
Amodiaquine Standard Curve. Figure 6.2 displays fluorescence plotted as a 
function of concentration of AQ. The fluorescence of Eosin-Y is quenched in the 
presence of AQ, with the quenching effect increasing with increasing AQ 
concentration. Fluorescence decreases linearly between 0.000 mg/mL and 0.027 
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mg/mL AQ.  
 
Stability of Amodiaquine in Presence of Ultrasound. Figure 6.3 displays the 
concentration of AQ measured in solution over 10 minutes of sonication at 50% 
amplitude setting. The measured concentration of amodiaquine is constant over 
10 minutes of exposure to sonication suggesting that ultrasonic agitation does not 
alter the detection and quantification of AQ in solution. 
 
Consistency of Automated Dilution Protocol. Figure 6.4 displays the dilution factor, 
or the factor by which the original AQ solutions were diluted, over 5 repeats. The 
system was able to achieve an average dilution factor of 180.6 with a coefficient 
of variation of +/- 2.4%. This dilution factor was slightly lower than expected, 
resulting in a slightly higher overall concentration of the diluted AQ samples, but 
the resulting concentration was still in the quantifiable range of the standard curve. 
 
 Determination of Time Required to Dissolve Camosunate and Winthrop Tablets. 
Figure 6.5 plots the amount of AQ in solution from dissolving Camosunate and 
Winthrop tablets. Both tablet types fully dissolve by 6 min. The Camosunate tablets 
show some variability in amount dissolved at early time-points, but all curves 
approach the same total amount dissolved. Winthrop tablets dissolve rapidly, and 
the amount of AQ in solution appears to start to decrease after 6 minutes of 
sonication. 
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Quantification of Amodiaquine from Tablets Dissolved by Mechanical and 
Ultrasonic Agitation. Figure 6.6 displays the amount of AQ dissolved from 
Camosunate and Winthrop tablets across the 3 sample preparation methods. The 
amount of AQ dissolved from Camosunate tablets was consistent across all 3 
methods and the total amount deviated from expected by less than 0.33% in all 
cases. The amount of AQ dissolved from Winthrop tablets was also consistent 
across all 3 methods, but the amount of AQ was about 3.5% lower than expected 
in all cases. These results suggest that dissolving Camosunate and Winthrop 
tablets by ultrasonic agitation and more traditional mechanical agitation 
approaches result in equal amounts of dissolved AQ, supporting ultrasonic 
agitation as a viable means of dissolving tablets. 
 
Repeatability of AQ Quantification from PharmaChk Instrument. Overall, 41 
Camosunate tablets and 38 Winthrop tablets were tested on the PharmaChk 
instrument. Figure 6.7A and 6.7B display histograms of quantified amount of AQ 
from Camosunate and Winthrop tablets, respectively. The average amount of AQ 
quantified from Camosunate tablets was 326.33 mg, about 8.7% higher than the 
expected amount of 300 mg. The coefficient of variation of quantified amount of 
AQ was 9.06%. Testing of Camosunate tablets was performed on 5 different 
microfluidic modules. One module on which 12 tests were performed consistently 
over-quantified with an average amount of AQ quantified over those 12 tests of 
364.67 mg. The average amount of AQ quantified from Winthrop tablets was 
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259.88 mg, about 3.7% lower than the expected value of 270 mg. The coefficient 
of variation of amount of AQ quantified was 9.35%.  
 
Field Test of PharmaChk Instrument with CePAT in Accra, Ghana – December 
2016 
Objectives 
 The PharmaChk instrument was tested in Accra, Ghana at the Center for 
Pharmaceutical Advancement and Training, a USP-sponsored medicine quality 
testing and training facility servicing countries in sub-Saharan Africa. The objective 
of this testing was to demonstrate the second version of prototype of the 
PharmaChk instrument which incorporated fully automated tablet dissolution and 
sample preparation; the first version of the prototype required manual tablet and 
sample preparation. The prototype was used to test Camosunate AQ and AS 
(artesunate) and Winthrop tablets, front-line antimalarial medications at the time, 
collected from local pharmacies and manufactures in Accra. Testing was 
performed by lab technicians at CePAT and FDA Ghana. All users were trained on 
how to use the instrument, and they were asked to complete a survey of their 
experience using the instrument at the end of testing. 
 
Results 
 Overall, 27 tests were performed across 5 tablet types, 4 tablets containing 
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AQ and 1 tablet containing AS. Deviations from the label claim of API in each tablet 
ranged from 4.7% to 14.4%. API content for all tablet batches was also analyzed 
by USP methods, and all medicines were found to fall within acceptable deviation 
ranges. Results from this testing are displayed in Figure 6.8. 
 
Preliminary Drug Release Testing Experiments 
Materials and Methods 
Materials. Amodiaquine hydrochloride (AQ) and Eosin Y were purchased from 
Sigma Aldrich (St. Louis, MO). Artesunate powder was purchased from TCI 
(Tokyo, Japan). Sodium Hydroxide was purchased from Merck KGaA (Darmstadt, 
Germany). Camosunate tablets containing 300 mg AQ (Batch: 1507232) and 
Winthrop tablets containing 270 mg AQ (Batch: 5MA304) were sourced from 
Accra, Ghana. Ultrapure water was obtained from Milli-Q filtration system. 
 
Release of AQ from Camosunate and Winthrop Tablets. Camosunate 
amodiaquine and Winthrop tablets were used as test tablets. 50 mL ultrapure water 
at 20 oC was used as the test media for both tablets, and all tests were performed 
in glass test tubes. Tablets were dissolved at 35% and 50% amplitude setting; 
ultrasonic agitation was applied continuously. Probe height was set to 60 mm. The 
media was sampled every minute for 6 minutes of ultrasonic cavitation. Three 
tablets were tested for each condition. An aliquot of the dissolved tablet solution 
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was removed at each time point from the test vessel and immediately filtered 
through a 0.2 µm pore syringe filter. Fluorescence of each sample mixed with 
Eosin-Y was measured as described above. Concentration of AQ was determined 
as described above. 
 
Quantification of Artesunate Using Multi-Sampling protocol. A 2.0 mg/mL AS 
solution in 0.1 N sodium hydroxide was prepared. An aliquot of this solution was 
used to prepare a second 0.4 mg/mL AS solution. The amount of AS in each 
solution was quantified on the PharmaChk instrument using a sampling-protocol 
that prepares and analyzes 5 samples over 20 minutes. The 0.4 mg/mL AS 
solution was measured for the first 2 samples and the 2.0 mg/mL solution was 
measured for the last 3 samples. AS was quantified using the luminol assay 
described in Ho et al.  
 
Results 
Release of AQ from Camosunate and Winthrop Tablets. Camosunate and 
Winthrop are two different brands of tablets containing approximately the same 
dosage of AQ in different formulations; Camosunate tablets contain AQ as the 
single while Winthrop tablets are co-formulated tablets containing both AQ and AS. 
The cumulative amounts of AQ released from Camosunate and Winthrop tablets 
at 35% and 50% amplitude setting are displayed in Figure 6.9A and 6.9B, 
respectively.  At an amplitude setting of 50%, both tablets approach complete 
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release of amodiaquine by 3 mins.  The Camosunate tablets display a lag in 
release over the first minute corresponding to the time until initial tablet fracture, 
followed by rapid release of amodiaquine due to continuing fracture of the tablet.  
Winthrop tablets fracture almost immediately after the application of ultrasonic 
cavitation and show an immediate increase in the amount of AQ released after 1 
min.  At an amplitude setting of 35%, Winthrop tablets show a lag in release over 
the first minute but still approach complete release by 3 minutes.  Camosunate 
tablets also display a lag in release over the first minute, followed by a more 
sustained release from 2-6 minutes.  At the lower amplitude setting, fracturing of 
the Camosunate tablet is less pronounced leading to slower release of API. 
 
Quantification of Artesunate Using Multi-Sampling protocol. The multi-sampling 
protocol is necessary to measure the amount of API in solution during a drug 
release test. This protocol differs from the end-point test in that multiple samples 
are taken from the dissolving tablet solution, and the sample channel in the 
microfluidic module undergoes an abbreviated cleaning procedure between 
samples. The amount of AS quantified over the 5 samples is shown in Figure 6.10. 
The AS solutions were introduced in increasing concentration to mimic the change 
in concentration during a drug release test. Each solution was measured multiple 
times to assess the consistency of AS quantification. The amount of AS in solution 
is accurately quantified over all samples. There does not appear to be any effect 
of changes in concentration in the quantification of subsequent samples. 
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Discussion  
 Post market surveillance of counterfeit and substandard medicines has 
proven to be a complex task, especially in low- and middle-income countries. 
These medicines can exist at any point along the supply chain within a country, 
from local pharmacies and chemical sale entities through storage facilities and 
distributors up to manufactures and ports of entry, with the ability to be added into 
the supply chain at any point along the way. Point of care testing options have 
expanded testing capabilities to various locations along the supply chain relieving 
the logistical and time burden of collecting medicines to test at central laboratories. 
The broad definitions of counterfeit and substandard medicines necessitate the 
use of multiple testing approaches. Current testing approaches apply 
chromatographic, chemical, and optical methodologies to perform API 
identification, impurity detection, and package inspection. Spectroscopic 
technologies allow for unique chemical fingerprints of dosage forms, but these 
technologies are very sensitive to minute changes in formulations and require 
comparison against difficult to prepare libraries. Identification and impurity 
detection are effective metrics in the detection of counterfeit products, but these 2 
metrics alone are not effective indicators of substandard products.  
Quantitative measures of medicine quality are a major requirement for the 
detection of substandard medicines. API content analysis takes identification a 
step further allowing for a direct comparison of amount of API present to the label 
claim. The GPHF MiniLab is the only product available for point-of-care testing that 
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provides semi-quantitative content analysis; the thin layer chromatography method 
detects whether API is present above or below 80% of the label claim. Dissolution 
and generalized drug release testing provide multiple metrics for assessing the 
rate of release of drug from solid dosage forms, including percent dissolved at 
specified time intervals, time intervals until a specified amount is released, 
dissolution efficiencies, and fitted model parameters. These methods also allow 
for direct comparison of release behavior between reference and sample dosage 
forms using average distances and analysis of variance approaches. These 
parameters provide crucial information on critical process parameters and critical 
material attributes of solid dosage forms allowing for the detection of abnormalities 
in tablet behavior caused by manufacturing and formulation differences; 
preliminary testing with Camosunate and Winthrop tablets demonstrate that 
differences in formulation result in detectable differences in release behavior (Fig. 
6.9). Said another way, drug release behavior provides another fingerprint of 
dosage form quality. No products on the market allow for either type of analysis. 
Feedback from the field trial regarding the capabilities of the PharmaChk 
instrument were very positive, in this light. Users appreciated the quantified 
amount of API from tablet samples provided at the end of each test. This 
information enables users to make real-time decisions about next steps and 
determine if follow-up testing is needed. Users envision that drug release testing 
data will further enable these decisions. Errors in API quantification were as high 
as 14% for some samples tested. The source of these errors was, in part, process 
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and assay related. The major issues regarding using the instrument were centered 
around preparing reference solutions for simultaneous measurement during tests. 
The second prototype of the PharmaChk instrument fully automated all steps 
related to preparation of the tablet sample, including dissolving the tablet, filtering, 
and performing any necessary dilution. Eliminating the liquid handling steps for 
reference solution preparation would greatly increase the usability of the 
instrument. Current development work has focused on addressing these issues. 
Conversations with potential users and other stakeholders in the medicine 
quality space have provided great insight into how an instrument like PharmaChk 
could be added to the repertoire of tools used for medicine quality testing. No field-
based tool, including PharmaChk, can replace official laboratory testing. These 
point of care tools ideally provide front-line screening of samples to determine if 
follow-up testing at central facilities is needed. In this role, point-of-care 
technologies improve the allocation of scarce resources available for post-market 
surveillance by reducing the number of expensive laboratory tests performed. Lab 
personal at CePAT and FDA Ghana were not very concerned with the levels of 
error observed during testing. As a screening technology, accuracy and precision 
are not held to as high of standards as typical laboratory instruments, and they are 
only one component of an effective technology; increasing the ability to test and 
access to this type of information are also important considerations. Portability and 
the ability to test at any point along the supply chain are key capabilities of the 
instrument. However, this type of testing may not always be possible due to the 
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current framework of and approaches to medicine quality testing in a given country. 
This information is important to keep in mind as the project moves forward. 
Fully incorporating drug release testing into the PharmaChk platform poses 
additional challenges on top of those associated with end-point testing. When 
performing an end-point test, the test time should be minimized to increase testing 
throughput. The sampling mechanism of the instrument places a limit on the 
frequency of sampling; currently 1 sample can be taken every 5-7 minutes 
depending on the sampling process. Drug release testing times will be dictated by 
the number of time-points needed to accurately describe the dosage form in 
question. Some immediate release tablets may only require one time-point to 
define drug release behavior while slower immediate release or extended and 
sustained release dosage forms may require more points over longer periods of 
time. The number of samples that can be taken during any one test is also limited 
by the volume of the sample. Samples are taken without replacement of media, so 
every sample decreases the media volume. The sampling volume limits these tests 
to 5 data points. Drug release data for tested samples will be compared to 
reference drug release data. Each brand of dosage form for every API tested will 
need to have its own reference data set if differences between formulations and 
manufacture quality are to be detected. 
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Figure 6.1. Schematic of API quantification on PharmaChk platform. 
Dissolved pill input and fluorescent tag input are mixed in milli-fluidic module. 
Emitted light is image using CCD camera. The magnitude of the light signal is 
dependent on sample concentration, and this magnitude can be used to determine 
the concentration of a sample solution when compared to a reference curve. 
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Figure 6.2. Standard Curve of Eosin-Y Assay Quantification of AQ. 
RFU values of Eosin-Y mixed with varying concentrations of AQ at 
excitation/emission wavelengths of 485nm/525nm. 
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Figure 6.3. Stability of Amodiaquine in Presence of Ultrasound. 
Quantified amount of AQ in solution over 10 min continuous exposure to ultrasonic 
agitation at 50 mm probe height and 50% amplitude setting. 
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Figure 6.4. Consistency of Automated Dilution Protocol. 
The dilution factor achieved by the automated dilution protocol over 6 trials. The 
average dilution factor was 178.7 +/- 3.5%. 
  
169
177 181 175
184 186
0
50
100
150
200
1 2 3 4 5 6
D
ilu
it
o
n
 F
ac
to
r
Run
168 
 
 
 
Figure 6.5. Determination of Time Required to Dissolve Camosunate and 
Winthrop Tablets. 
The amount of AQ dissolved from Camosunate (squares) and Winthrop 
(diamonds) tablets over 10 min in presence of ultrasonic agitation at probe height 
of 35 mm and amplitude setting of 50%. Each tablet type was tested in triplicate. 
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Figure 6.6. Quantification of AQ from Tablets Dissolved by Mechanical and 
Ultrasonic Agitation. 
The total amount of AQ quantified in Camosunate and Winthrop tablets prepared 
by multiple agitation and filtering methods. Data are plotted as the average and 
standard deviation of 3 tablets. 
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Figure 6.7. Repeatability of AQ Quantification on PharmaChk Instrument. 
(A) Quantification of AQ from 41 Camosunate tablets. Testing was performed 
using 5 different fluidic modules. Each module had its own level of average 
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quantification and variability. (B) Quantification of AQ from 38 Winthrop tablets. 
Testing was performed using 2 different microfluidic modules. 
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Figure 6.8. Quantification of AQ and AS from Camosunate and Winthrop 
Tablets. 
Results from tablet testing performed at CePAT and FDA Ghana during December 
2016 field trial. 27 tests were performed over 5 tablet types – Camosunate AQ (7), 
Winthrop AQ (child, 3), Winthrop AQ (adult, 1), Amofan AQ (1), Camosunate AS 
(15). Data (orange) plotted as average +/- standard deviation compared to 
expected amount of API (blue) from label claim. 
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Figure 6.9. Drug Release Profiles of AQ from Camosunate and Winthrop 
Tablets. 
Release profiles of AQ from Camosunate (squares) and Winthrop (diamonds) anti-
malarial tablets at 35% (A) and 50% amplitude setting (B).  Probe height was fixed 
at 60mm; ultrasonic agitation was administered continuously. Data plotted as 
mean amount of AQ +/- standard deviation over 3 trials. 
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Figure 6.10. Quantification of AS Using Multi-Sampling Protocol. 
Amount of AS quantified in solution using multi-sampling protocol on PharmaChk 
instrument. The expected concentration of the first 2 samples was 20%, and the 
expected concentration of the last 3 samples was 100%. Blue bars are expected 
values; orange bars are experimental values. Data are from 1 run consisting of 5 
consecutive reads. 
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CHAPTER 7: CONCLUSION 
 
This dissertation presented an alternative, quantitative approach to drug-
release testing using ultrasonic agitation in a low-volume environment aimed at 
addressing short-comings and expanding the scope of current dissolution 
methods. Ultrasonic agitation was demonstrated as a viable method to achieve 
highly repeatable and tunable drug release from multiple types of solid dosage 
forms. The hydro-acoustic environment and drug release behavior were 
characterized across two systems parameters, input power of the acoustic signal 
and placement of the acoustic source. A deterministic partial differential equation 
framework was developed to explore the dynamic interplay between diffusion and 
fragmentation during solid dissolution processes. The use of the ultrasonic 
agitation mediated release test was then demonstrated at two different stages of 
the drug development process – experimental dosage form development and post 
market surveillance.  
 
Impact and Innovation 
The ultrasonic agitation mediated drug release test provides a low-volume 
screening tool to assess dosage physical and material properties. This method 
would be a supplement to, not a replacement of, official dissolution testing. In the 
cases of early stage formulation development and post market surveillance, this 
approach can be used to identify samples that require follow-up testing with official 
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methods, reducing cost and time burdens of performing official tests on 
unnecessary samples.  
Preliminary experiments with stirring-based approaches for drug release 
testing at small volumes posed unique challenges with partitioning the stirring 
element from dissolving tablets. In Chapter 3, ultrasonic agitation was explored as 
an alternative to these approaches because the application of ultrasound was 
shown to enhance solid dissolution processes. However, prior uses of ultrasound 
in solid dissolution have focused on the rapid and efficient processing of 
solutes77,160. The results presented in this dissertation present a new, and 
surprising, application of ultrasonic agitation for controlled and tunable drug 
release testing from solid dosage forms. Drug release behavior from tablets was 
found to fall into 3 regimes – slow, fast, transition – depending on the amplitude 
setting of the ultrasonic source. Characterization of the hydro-acoustic 
environment and observations from release testing experiments revealed that 
these regimes were defined by the level of convective flow generated from the horn 
and cavitation threshold effects. Acoustic streaming was observed to result in 
vortical flow structures throughout the vessel punctuated by regions of apparently 
turbulent behavior. These findings elucidated connections between the hydro-
acoustic environment inside an ultrasonic reactor and tablet breakdown and drug 
release behavior. These connections can help inform future ultrasonic reactor 
design.  
The deterministic PDE model of solid dissolution processes, discussed in 
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Chapter 4, adds to existing literature on dissolution modeling by examining the 
process from a distribution standpoint and actively tracking time-evolving particle 
size distributions. The inclusion of fragmentation provides a better physical 
representation of the tablet dissolution process, especially in cases where 
disintegration is a major mechanism in release behavior. This model allowed for 
the decoupling of diffusion and fragmentation phenomenon and the study of their 
impact on particle size distributions throughout the process. The bulk rate of 
dissolution was found to be heavily dependent on the time-evolution of surface 
area throughout the process. These findings highlight the importance of quality 
control in the manufacturing of dosage forms, as changes to the process that effect 
granule or disintegration properties can have huge impacts on drug release. 
Unburdened by the constraints imposed by current assumptions and 
approaches to dissolution testing, the alternative approach to drug release testing 
was applied to testing at 2 different stages of the drug development process. Low-
volume drug release presents a boon for testing during experimental and early 
stage formulation development where production of material is a bottleneck; the 
methods described in the production of the composite microparticle systems 
generate particles on the milligram to sub-gram scale making production for drug 
release testing by official methods costly and time-consuming. The low-volume 
method presented here only required 1-2.5 mg of drug per test, as opposed to 20+ 
mg required by official methods. In Chapter 5, the ultrasonic agitation mediated 
method was used to assess how structural changes in composite microparticles 
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affects release behavior. The fine level of structural control afforded by these 
methods may allow for the production of designer dosage forms with tunable 
release profiles. 
Low-volume methods of drug release testing also enable portable and point-
of-care testing for post-market surveillance of substandard products. The 
ultrasonic mediated method was shown to be discriminatory to differences in 
formulations containing the same API. The ultrasound system was incorporated 
into the PharmaChk platform for portable and automated drug release testing 
being developed by the Zaman lab. The platform was demonstrated in the fully 
automated quantification of API amount in anti-malarial tablets using ultrasonic 
agitation as the sample preparation method. This work represents important 
strides towards enabling the detection of substandard medicines at the point-of-
care. 
 
Limitations 
 The use of ultrasonic agitation and the potential necessity of co-solvent 
systems to achieve full solubility of hydrophobic APIs precludes the ability of this 
test to provide information of in vivo behavior of dosage forms. The main utility of 
this test is as a screening method for dosage structural and material properties, 
where samples that are identified as of interest can then passed on for analysis by 
official dissolution methods. 
Preliminary experiments with alginate hydrogel particles suggest that the 
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ultrasonic agitation release method may not be compatible with every type of 
dosage form sample. Ultrasonic agitation may accelerate or otherwise induce the 
degradation of dosage form structure or negatively interact with the dosage form 
in a manner that confounds release behavior. Future studies should focus on 
defining the API and formulation space that is compatible with this test method. 
 The hydro-acoustic environment inside the ultrasonic reactor is very 
sensitive to a range of parameters as demonstrated here and in the 
literature96,98,161. Factors such as horn size, vessel geometry, and system 
boundary conditions all dictate system performance. The composition and level of 
dissolved gas in a given media can also alter acoustic propagation. Understanding 
the effects of perturbations on these parameters is crucial in defining optimal test 
parameter spaces. 
 
Future Directions 
 Future work in system development could focus on optimizing the design 
for different use cases. The ultrasonic generator, horn, and test vessel were all off 
the shelf-components, and these components were held constant across 
applications. Custom components could be designed for specific use cases. 
Ultrasonic agitation could also be achieved through indirect means, either by 
coupling the acoustic source to the outer wall of the vessel or a secondary liquid 
surrounding the vessel. Indirect coupling would simplify the internal environment 
of the ultrasonic reactor and reduce the possibility of sample cross-contamination. 
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 One immediate follow-up to the model presented in Chapter 4 would be the 
experimental validation of particle size distributions. Composite polymeric 
microparticles provide a good model system to approach this problem. 
Microparticles can be direct compacted into tablets, where the release 
characteristics of the fundamental particle unit are well defined due to the fine 
control over particle structure and size. An understanding of how particle size 
distribution changes over the release process can provide another design 
parameter with which to tune release behavior. 
 The spaces of API and formulation type that are compatible with the test 
need to be further defined. This knowledge will help inform test parameters for new 
dosage forms. The low volume nature of this test may require the use of co-solvent 
systems to achieve sink conditions for hydrophobic and other high dosage 
medicines. Drug release behavior could be studied as a function of dosage form 
physical properties and media properties to identify potential regimes of release 
behavior. The fracture and diffusion model would be able to provide insight into the 
relative contributions of each process in these regimes as well as the effects on 
the evolution on particle size distributions. A complete understanding of the test 
space is an important step towards using the ultrasonic agitation mediated test for 
the retroactive assessment of critical process parameters and critical material 
attributes of dosage forms. 
 Historically, the detection of substandard medicines has proven to be a 
difficult task in part due to the broad definition of substandard. In order to effectively 
181 
 
 
screen for substandard medicines, any drug release test would need to be 
sensitive to a wide range of possible discrepancies in a given dosage form. Results 
presented in this dissertation demonstrate that the ultrasonic agitation mediated 
drug release test is sensitive to dosage form structure and formulation in select 
cases. The discriminatory power of the test needs to be further assessed across a 
wide range of possible differences. Composite microparticle samples also act as a 
useful model system to assess the discriminatory in a controlled manner. Custom 
tablets could also be produced to mimic possible causes of substandard dosage 
forms. 
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APPENDIX 
 
A. Engineering Drawings of the Dissolution Stand 
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B. SOP for Ocean Optics Based Continuous Sampling Set up 
Ultrasound-Mediated Drug Release Testing 
System Priming 
1. Connect flow-cell input tubing downstream of peristaltic pump tubing. Run 
peristaltic pump at 24.0 rpm to fully prime entire length of connected tubing 
with test media. 
2. Place cannula filter to end of sampling tubing. Using a syringe, fully wet the 
filter and prime the tubing with test media. 
3. Quickly connect sampling tubing upstream of peristaltic pump, and 
submerge the input end of the tubing into a beaker containing test media 
such that the top of the syringe filter is ~5 mm below the surface of the 
media. Run peristaltic pump at 24.0 rpm until entire length of connected 
tubing is fully wetted. 
4. Using the syringe in step 2, pass test media through syringe filter to fully 
wet the inside of the filter.  
5. Connect the syringe filter directly upstream of the peristaltic pump between 
the peristaltic pump tubing and the flow-cell input tubing. Run peristaltic 
pump at 24.0 rpm until all connected tubing is fully wetted and a continuous 
flow from the outlet of the syringe filter is achieved. 
6. Connect flow-cell input and output tubing to the input and output of the flow-
cell, respectively. Run peristaltic pump at 16.0 rpm for 5 min. 
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UV-Vis and Software Preparation 
1. Connect fiber optic cables from light source to the flow-cell and from the 
flow-cell to the Ocean Optics Flame spectrophotometer. 
2. Connect the spectrophotometer to a lab containing the OceanView software 
using the included USB cable. 
3. Turn on Ocean Optics light source. Turn on Deuterium lamp and wait for 
indicator light to stop flashing. Allow 5 min for lamp to warm up. 
4. Open the OceanView software. Click on the Spectrophotometry Wizard, 
then click on the tab labeled Absorbance. 
5. Open the lamp and set the integration time of intensity measurements by 
clicking the “Automatic” button. (typical integration times for the 20 mm path 
length flow cell range from 40 -100 ms.) 
6. Set the number of Number of Scans to Average to 5 and set the Boxcar 
Number to 5. Click next. 
7. With the lamp still open, capture the reference spectra. Click next. 
8. Close the lamp and capture the background (dark) spectra. Click finish. 
9. To track the intensity at a specific wavelength over time, click on the “Create 
Strip Chart” button. On Follow the steps in the wizard to adjust the display 
settings and indicate the measurement wavelength. On the first page, make 
sure the top line is selected to record Intensity. On the second page, set the 
number of scans on “Update plot after” such that the plot updates 
approximately every 1 sec. On the third page, leave all settings as default. 
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On fourth page, specify the wavelength for which you want to measure the 
intensity. Click finish. 
10. Set the data acquisition and saving parameters by clicking the “Configure 
Data Settings” button. Select Time Course as the file type from the drop-
down list. Identify the directory and filename base of the data file. Select 
“save first scan after” and set the time to 5 sec. Check the box next to “Stop 
saving after” and set the time to the duration of the release test – the total 
test time should allow for an 80 sec baseline collection before the sample 
is added, the entire sonication time, and an additional 5 min of data 
collection after the end of sonication. 
11. Click apply and exit the menu.  
Ultrasound Setup Preparation 
1. Power on the ultrasound unit. Set the amplitude to the required amplitude 
for the release test. Make sure the horn is connected to the ultrasound unit. 
2. Set the height of the probe holder to the specified probe height for the test. 
3. Set the duration of sonication and the pulse characteristics of the ultrasound 
dosage (1 Hz, 50% duty cycle – i.e. 500 ms/500 ms pulse on/pulse off). 
(Note: depending on the ultrasonic generator unit, the dosing/pulsing may 
need to be controlled externally using a microcontroller).  
4. Insert the test vessel into the holder on the stand and secure in place. Add 
50 mL of test media to the vessel. 
5. Insert the sample tubing into the test vessel, making sure the cannula filter 
191 
 
 
is fully submerged. Insert the free end of the flow-cell output tubing into the 
test vessel. 
Performing a Release Test 
1. Weigh out the amount of sample to be tested and set aside.  
2. Start the data acquisition. 
3. Add the sample to the test vessel after 80 sec. Insert the horn into the holder 
such that the tip is submerged in the test media and start the sonicator. Note 
the start time of sonication. 
4. Allow test to run. 
5. After sonication is completed, continue recording data for 5 min. 
System Cleaning 
1. After data acquisition is complete, remove the horn from the holder and 
clean the tip by wiping it with 70% ethanol solution. 
2. Turn off the peristaltic pump. Remove the syringe filter from the sampling 
loop. Set the pump speed to 24.0 rpm. 
3. Remove the sampling tubing from the test vessel. Remove the cannula filter 
and clean the outside of the tubing. 
4. Remove the flow-cell output tubing from the test vessel and place in a waste 
container. 
5. Turn on the pump to allow a small volume of air to be inserted into the 
system. Insert the end of the tubing into a beaker containing test media and 
flush system for 10 min. 
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6. After 10 min, turn off pump. Completely empty and dry all tubing. 
7. Empty and clean the test vessel.  
 
Initial System Setup and Characterization (to be performed when setting up 
new instances of the system) 
1. Tubing lengths and ID should be chosen such that the total dead-volume of 
the system is minimized while ensuring that tubing is able to start and 
terminate in the test vessel and the pressure drop across the system does 
not prevent flow throughout the system. 
2. To calculate total system dead-volume, start with a known mass of water in 
a beaker. Completely fill the sampling system with water. Determine the 
new mass of the water in the beaker. The difference in mass should be the 
amount of water in the sampling system. 
3. To calibrate pump flow-rates, run the pump over a range of rpm values. 
Measure the mass of water dispensed from the fully set up system after a 
specified amount of time at each rpm. 
4. The time lag in absorbance measurements due to system dead-volume 
needs to be empirically determined. The syringe filter acts as a fluid 
reservoir where solute concentration is constantly increasing over time, 
making the calculation of lag time from the system dead-volume and test 
flow-rate inaccurate. 
Notes/Comments: 
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- System dead-volume and pump speeds 
o Pump speeds were determined empirically and are dependent and 
pressure drop across system and the pump being used. A pump 
speed of 16.0 rpm was found to correspond to a flowrate of ~1.0 
mL/min. A pump speed of 24.0 was chosen as an arbitrarily high 
speed to facilitate system priming and cleaning. 
o The tubing lengths and sizes used should be minimized without 
affecting pumping consistency. 
o The dead-volume and pressure drop across the system directly 
affect the residence time of sampled liquid. This time needs to be 
determined beforehand and should be held constant across all tests 
as system residence time is reflected in the absorbance vs time data. 
- Sensitivity of the intensity measurements. 
o The optical connections between the lights source and 
spectrophotometer are fiber optic cables. The light intensity reaching 
the spectrophotometer detector is VERY sensitive to movements of 
the fiber optic cables. The cables must NOT be touched after the 
system is setup and while the test is running. 
- OceanView Software 
o The OceanView software allows for recording of intensity or 
absorbance at a specific wavelength. The software only records the 
absorbance to 3 significant digits which does not provide enough 
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resolution at the early stages of the release test. Although 
absorbance is the measurement of interest, it is recommended that 
intensity is recorded and then converted to absorbance.  
- Controlling ultrasound pulse characteristics 
The ultrasonic horn is operated in a pulsed regime to minimize heat generation. 
The unit used for the demonstration does not include internal pulsing controls. An 
Arduino and relay switch was used to externally control pulsing. 
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